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Določitev kanabidoidnih receptorjev v celičnih linijah raka dojke 
Razširjeni povzetek 
Rak dojke je najpogostejša malignost pri ženskah, saj je letno na svetu diagnosticiranih več kot  
1,5 milijona novih primerov bolezni. Opredeljeni so bili različni dejavniki tveganja, kot so 
hormonski in genski dejavniki ter življenjski slog, za katere je dokazano, da povečujejo verjetnost 
za nastanek raka dojke.  
Glede na prisotnost molekularnega markerja so opredeljeni trije podtipi bolezni: za hormonski 
receptor pozitivni (HR+), za humani epidermalni rastni faktor 2 pozitivni (HER2+) in trojno 
negativni rak dojke. Podtipi delujejo kot vodilo pri diagnozi, prognozi in sistematičnem 
zdravljenju bolezni. Sistematično zdravljenje se uporablja za zaustavitev razvoja in preprečitev 
ponovitve bolezni. 
Najpogostejši podtip raka dojke je HR+, s prevalenco med 60 in 70 %. Znotraj podtipa HR+ je 
opaženo izražanje estrogenskega (ER) in progesteronskega receptorja (PR), ki služita kot markera 
in tarči za zdravljenje. Standardno sistemsko terapijo sestavljajo zaviralci jajčnikov (OS), 
inhibitorji aromataze (AIs) in selektivni modulatorji estrogenskih receptorjev (SERM). 
Tamoksifen (TAM), nesteroidni antagonist ER, ki ima sposobnost vezave na ER-receptorje v 
nanomolarni koncentraciji, je najbolj pogosto uporabljeno zdravilo za HR+ rak dojke.  
Drugi najpogostejši podtip je HER2+, s prevalenco med 20 in 30 %. Značilno je prekomerno 
izražanje receptorja HER2. Zlati standard v zdravljenju podtipa HER2+ je humanizirano 
monoklonsko protitelo, ki cilja zunajcelično domeno HER2, trastuzumab (blagovna znamka 
Herceptin, HER). Pred razvojem trastuzumaba je bil zaradi pomanjkanja sistemske terapije ta 
fenotip povezan z zelo slabo prognozo. 
Tretji znani podtip je trojno negativni rak dojke, ki je najmanj pogost, a najbolj agresiven fenotip, 
povezan s slabo prognozo. V primerjavi s podtipoma ER+ in HER2+ trojno negativni rak nima 
molekularne tarče, ki bi zavrla razvoj bolezni. Standardna terapija pri trojno negativnem raku je 
kombinacija kemoterapije in radioterapije. Cisplatin (CIS) je eden od prvih odkritih 
kemoterapevtikov s klinično uporabo iz poznih sedemdestih let prejšnjega stoletja. CIS zavira 
celično delitev s tvorbo dvojnih prelomov DNA, ki jih rakave celice ne morejo uspešno popraviti 
zaradi pogosto mutiranih mehanizmov popravljanja poškodb DNA. 
Endokanabinoidni sistem (ECS) je sestavljen iz kanabinoidnih receptorjev (CBs), endogenih 
kanabinoidov in encimov, vključenih v biosintzne in razgradne poti endokanabinoidov. Doslej so 
odkrili dve vrsti receptorjev: kanabinoidni receptor tipa 1 (CB1) in kanabinoidni receptor tipa 2 
(CB2). Oba receptorja sta povezana z G-proteini (GPCR), in sodelujeta pri različnih celičnih 
mehanizmih in v nevronih pri kognitivnih procesih. 
CB1 je bil prvi odkriti receptor ECS, ki vsebuje 2 znani izoobliki, se je pretežno izraža v 
centralnem in perifernem živčnem sistemu. Izražanje ni omejeno samo na živčni sistem, prisotno 
je tudi v drugih perifernih tkivih, kot so kardiovaskularni, gastrointestinalni, imunski sistem itd. 
Vloga CB1 v perifernih tivih še ni dovolj poznana. Dokazano je, da je receptor CB1 lokaliziran na 
  
 
plazemski membrani, vendar so raziskave pokazale, da obstajajo internalizirani (endosomi) in 
intracelularni predvsem mitohondrijski, pa tudi lizosomski receptorji. Po aktivaciji CB1 lahko 
deluje inhibitorno ali aktivacijsko na različne encime in signalne poti, ki posledično spodbujajo 
celično preživetje ali smrt, odvisno od vrste vezanega liganda in celičnega okolja. 
Drugi odkriti receptor ECS je CB2, ki se enako nahaja v dveh znanih izooblikah in se pretežno 
izraža v imunskem sistemu (v celicah, kot so bazofilci, eozinofilci, NK-celice, nevtrofilci, 
makrofagi, itd.). Nove raziskave so pokazale, da je receptor CB2 prisoten tudi v periferiji in v 
možganih. Čeprav signalne poti CB2 niso tako dobro poznane kot pri CB1, je glavna vloga CB2 
pri sprožitvi provnetnih ali protivnetnih učinkov imunskih celic.  
Obstajajo tri vrste spojin, ki lahko sprožijo aktivacijo ECS: endokanabinoidi, fitokanabinoidi in 
sintetični kanabinoidi. Endokanabinoidi so endogeno sintetizirane signalne lipidne molekule, ki 
imajo sposobnost vezave na CB-receptorje. Anandamid (AEA) in 2-arahidonoilglicerol (2-AG) 
sta najbolj znana endokanabinoida, ki delujeta kot agonista CB-receptorjev, imata različne 
lastnosti, način delovanja, pot sinteze in razgradnje. Fitokanabinoide najdemo pretežno v rastlini 
C.sativa L., ki vsebuje več kot 120 kanabinoidov. Najbolj pogost fitokanabinoid je  
Δ9-tetrahidrokanabinol (Δ9-THC), psihoaktivna spojina, in kanabidiol (CBD), ki je zaradi svojih 
potencialnih terapevtskih lastnosti postal zanimiv v zadnjih letih. Tretja vrsta kanabinoidov so 
sintetični kanabinoidi, ki so sintetizirani mimetiki fito in endokanabinoidov. Sintetične 
kanabinoide so razvili za eksperimentalne in terapevtske namene.  
Povezava med ECS in njegovim potencialom kot terapevtsko tarčo so prvič opazili pred 35 leti. 
Pri nekaterih boleznih je ECS spremenjen, stopnje izražanja CB-receptorjev so različne, prav tako 
ravni endokanabinoidov. Danes obstajajo dokazi o pozitivnih učinkih kanabinoidov pri zdravljenju 
nevropatske bolečine, multiple skleroze (MS), epilepsije in raka (paliativno zdravljenje). Pri 
zdravljenju zgoraj navedenih patologij je bilo odobrenih več zdravil na osnovi kanabinoidov, kot 
so Nabilon, Dronabinol, Nabiximols, itd. 
Potencial kanabinoidov pri zdravljenju intenzivo proučuje, klinična preskušanja pa potekajo pri 
boleznih z različnimi nevrološkimi motnjami (Parkinsonova, Alzheimerjeva, Huntingtonova), 
psihičnimi motnjami, posttravmatskimi stresnimi motnjami (PTSP), Tourettovim sindromom, 
anksioznimi motnjami, glavkomu in raku (možgani, dojka, prostata, kosti, koža, maternični vrat, 
trebušna slinavka, levkemija itd.). 
Razen paliativne terapije  raka so različni in vivo ter in vitro poskusi pokazali, da imajo kanabinoidi 
protitumorske učinke ter da vplivajo na celične procese, kot so celični cikel, proliferacija, smrt, 
migracija/invazija rakavih celic in angiogeneza/metastaziranje. 
Namen dela, cilji in hipoteze 
V magistrskem delu smo želeli (1) določiti ravni izražanja kanabinoidnih receptorjev in (2) učinke 
samega kanabidiola (CBD) ali v kombinaciji s pogostim za fenotip specifičnim terapevtikom na 
izbrane celice raka dojke. Predpostavili smo, da bosta raven izražanja receptorjev CB1 in CB2 
ustrezala biološkim vplivom CBD-ja na preživetje celic. 
  
 
Rezultati 
Ad 1. V sklopu naloge smo preizkusili eno od najbolj uporabljenih komercialnih poliklonskih 
protiteles proti CB1 in proti CB2 (proizvajalca Abcam) in bili med prvimi, ki smo testirali novo 
monoklonsko protitelo proti CB1 in proti CB2 (proizvajalca Santa Cruz Biotechnology). Določili 
smo specifičnost izbranih protiteles in ovrednotili izražanje CB1 in CB2 v izbranih celičnih linijah 
raka dojke različnih podtipov in z različnim statusom receptorjev. Izbrali smo humane nesmrtne 
celične linije raka dojke: MCF-7 (ER+/PR+/HER2-), MDA-MB-231 (trojno-negativna), MDA-
MB-361 (ER+/PR+/HER2-), SK-BR-3 (ER-/PR-/HER2+) in T-47D (ER+/PR+/HER2-). Celice 
smo gojili po protokolih ATCC in dobili pričakovane morfologije.  
Izražanje CB-receptorjev smo določili z dvema izbranima metodama: z metodo prenosa western 
(WB) in imunocitokemijo (ICC). Za analizo s prenosom western smo iz celičnih linij pridobili 
celične oborine, iz katerih smo ekstrahirali proteine z RIPA pufrom. Za pozitivne kontrolne celice 
smo izbrali nerakotvorno celično linijo MCF-10 in celice, izolirane iz pacienta z možganskim 
tumorjem (glioblastomom). Oba seta protiteles se vežeta na CB1 in CB2, a z različnima 
intenzitetama v izbranih celičnih linijah raka dojke. Protitelo proti CB1 podjetja Abcam lahko 
zazna CB1 samo v dimerni obliki, s signali, ki ustrezajo dvojni molekulski masi CB1. Pri 
protitelesu proti CB2 proizvajalca Abcam opazimo dimerne in monomerne signale. Protitelesa 
proti CB1 in CB2 proizvajalca Santa Cruz uspešno zaznajo signale specifične velikosti za  
CB-receptorje. Rezultate smo kvantificirali in normalizirali glede na hišni protein GAPDH. 
Tu prvič poročamo o izražanju CB-receptorjev v celičnih linijah SK-BR-3 in MDA-MB-361. 
Pokazali smo, da poleg CB2 celice SK-BR-3 izražajo tudi CB1. Pokazali smo tudi, da celična linija 
MDA-MB-361 izraža oba CB-receptorja, vendar z različno intenzivnostjo. Pri imunocitokemijskih 
rezultatih ni bilo enotnega obarvanja med testiranima celičnima linijama raka dojk. Protitelesa 
podjetja Santa Cruz proti CB1 so neustrezna za metodo ICC in rezultati niso primerljivi z WB. Pri 
Abcamovom protitelesu proti CB1 in Santa Cruzovemu proti CB2 smo opazili signal, vendar je 
potrebna dodatna validacija zaradi nespecifičnosti in opažene neobičajne lokalizacije (jedrno 
barvanje). 
Ad 2. Drugi cilj naloge je bil ugotoviti vpliv CBD na celično viabilnost, samostojno ali kombinaciji 
z specifičnim terapevtikom, kar smo določali s testom MTT. Za ER+ smo zbrali linijo T-47D in 
terapevtik tamoksifen, za HER+ SK-BR-3 in terapevtik Herceptin ter za trojno negativno  
MDA-MB-231 in terapevtik cisplatin.  
Metabolni testi so pokazali, da CBD zmanjšajo viabilnost celic v vseh testiranih celičnih linijah, 
bodisi na način, ki je odvisen od koncentracije (T-47D) ali praga odgovora (SK-BR-3,  
MDA-MB-231). Za vse tri linije smo izračunali vrednosti IC50 za CBD. Po našem vedenju smo 
bili prvi, ki smo testirali in prikazali CBD v kombinacijski terapiji z zgoraj navedenimi terapevtiki 
(TAM, HER, CIS). Možen sinergizem med CBD in terapevtiki smo opazili v vseh preizkušenih 
celičnih linijah, kar je obetavno za nadaljnje raziskave vpliva ECS pri zdravljenju raka dojke. 
Ključne besede: rak dojke, endokanabinoidni sistem, receptorji CB1, receptorji CB2, kanabidiol 
  
 
   
  
 
Characterization of cannabinoid receptors in breast cancer cell lines  
Abstract: 
Breast cancer is the most common malignancy in women across the globe, with over 1.5 million 
new cases reported yearly. Apart from invasive methods, phenotype-specific system therapy is 
used in suppression of disease development and recurrence. Recent research revealed that the 
endocannabinoid system (ECS) is involved in many diseases, including cancer. The 
endocannabinoid receptors are receptors associated with G-proteins, which are found in the central 
nervous system (Type 1 receptor, CB1) and the immune system (Type 2 receptor, CB2). While 
some cannabinoids (such as tetrahydrocannabinol, THC) are associated with psychotropic effects 
when bound to (CB1), others (such as cannabinol, CBD) have a plethora of biological effects, 
indicating their potential therapeutic value. 
In this Master Thesis we aimed to reveal (1) the expression levels of cannabinoid receptors and (2) 
the effects of cannabidiol (CBD) on cell viability alone, or in combination with commonly used 
phenotype-specific therapeutic on selected breast cancer cells.  
We hypothesized that the selected breast cancer cell lines express CBs on a protein level and that 
receptor CB1 and CB2 levels would correspond to the biological effects of CBD on cell viability.  
We evaluated the expression of CB1 and CB2 in breast cancer cell lines of different subtypes and 
receptor status (ER+/PR+/HER2-, ER-/PR-/HER2+ and triple-negative). The expression levels of 
CB1 and CB2 receptor proteins were analyzed using western blot (WB) and immunocytochemistry 
(ICC) method, comparing two different sets of primary antibodies. We tested one of the most used 
commercial polyclonal antibodies (manufactured by Abcam) against both CBs, and were among 
the first to test the new monoclonal antibody (manufactured by Santa Cruz Biotechnology) against 
both CBs. Both sets of antibodies successfully detected CBs in selected cell lines with the WB 
method, with rather different specificity. No constant pattern of expression was observed with the 
ICC method, as receptor staining highly varied amongst tested cell lines and antibodies.  
With the cell viability assay, we also tested the therapeutic potential of cannabidiol (CBD) alone, 
or in combination with common phenotype-specific therapeutics. Tamoxifen was used for 
hormone receptor-positive (ER+, PR+) T-47D, Herceptin (HER) for human epidermal growth 
factor 2 receptor positive (HER+) SK-BR-3 and cisplatin (CIS) for triple-negative (ER-, PR-, 
HER-) MDA-MB-231 cell line. CBD treatment alone was shown to decrease cell viability in all 
tested cell lines, in either a concentration-dependent (T-47D) or threshold response (SK-BR-3, 
MDA-MB-231) manner. To our knowledge, we were the first to test and show CBD effects in 
combination with the above listed therapeutics. Possible synergism between CBD and therapeutics 
was observed in all tested cell lines, which holds a promising potential for further exploitation of 
ECS in treatment of breast cancer.     
Keywords: Breast cancer, cannabinoid receptors, CB1, CB2, cannabidiol  
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1 INTRODUCTION  
1.1 Breast cancer  
Apart from nonmelanoma skin cancer, breast cancer is the most common malignancy in women 
across the globe. The two most common histological types are invasive ductal carcinoma, which 
accounts for over a half of diagnosed breast malignancies, and invasive lobular carcinoma, with 
an average prevalence of 5 % to 15 %. Each histological type is further grouped into three subtypes: 
hormone positive, HER2 positive and triple-negative breast cancer. These subtypes act as a guiding 
light in disease prognosis and system therapy administration. The most common detectable 
symptom is the formation of a palpable breast mass, often referred to as breast lump. Less present 
symptoms are: axillary mass formation, changes in breast symmetry, size or shape, visible skin 
changes around the breast (erythema, skin thickening), nipple inversion and discharge [1]. After 
the onset of the listed symptoms, diagnostic procedures are used to confirm cancer diagnosis. The 
most common and effective procedure is a diagnostic and screening method known as 
mammography, which is based on low energy X-ray imaging. Other available diagnostic methods 
are ultrasonography, MRI, PET and physical examination [2].  Once the tumor has been diagnosed, 
it undergoes classification to assess the severity of the disease [3]. Each tumor is staged based on 
three criteria (TNM system); Primary tumor size and location (T), Regional lymph node metastasis 
(N) and distant metastases (M) [2,3].  
1.1.1 Breast cancer risk factors 
Various risk factors have been identified, which are shown to increase the probability of 
developing breast cancer. A well-established correlation exists between hormones, pregnancy and 
cancer development. Natural occurring hormone-dependent changes in the female body, like early 
menarche and later onset menopause have been associated with higher disease risk, while early 
first birth and breast feeding lowers the risk of disease development. Long term exogenous 
hormone exposure in the form of oral contraceptives, hormone-replacement therapy and high 
testosterone levels have been connected with increased risk in both premenopausal and 
postmenopausal women [2,3]. Interestingly, no correlation exists between abortion and breast 
cancer [3]. 
Apart from hormone-related risks, genetics and lifestyle have also been identified as risk factors 
[2,3]. The risk of breast cancer development increases with age, with the most common diseases 
onset between the ages of 40-59, while also being fairly rare up to the ages of 39 [3]. The majority 
of breast cancer cases are sporadic, with approximately a quarter being family related [4]. Family 
history of breast cancer, especially amongst first degree relatives, increases the risk of cancer 
development [3]. This can be explained with the correlation between familiar breast cancer and 
susceptibility genes [4]. Family-linked studies identified and showed that gene susceptibility 
differs, as it can be high (BRCA1, BRCA2, PTEN, TP53), moderate (CHEK2, ATM, BRIP1, 
PALB2, RAD51C) or low-penetrance (CASP8, TNRC9, MAP3K1, LSP1). The degree of 
penetrance correlated with the increased risk of inherited syndrome development is 40-85 % during 
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the course of a lifetime [3,4]. The majority of identified genes are involved in the DNA repair 
mechanism, with BRCA1 and BRCA2 being the best characterized ones [4,5]. Aside from DNA 
repair, BRCA genes act as tumor suppressors in cell cycle control, cell division and maintaining 
genome integrity [5]. The involvement of BRCA genes in development of familiar breast cancer 
has been well established since the early 1990s, as autosomal dominant mutations in BRCA1 and 
BRCA2 lead to genomic instability, and increase the risk for diseases development up to 65-81 % 
and 45-85 %, respectively [3,5]. Today, BRCA1 and BRCA2 genes are used as diseases prediction 
models, and are often precautionary screened for mutations in familiar breast cancers [4]. 
Individual modifiable lifestyle factors, such as physical activity, obesity, dietary habits and 
environmental exposure, effect disease appearance in either a positive or negative manner. It is 
well established that a healthy lifestyle decreases the probability of developing any disease, 
including breast cancer. Positive lifestyle factors, such as physical activity lowers probability, 
while negative factors such as obesity and consumption of high-fat diary food and red meat 
increases disease probability. Interestingly, regular alcohol consumption increases disease risk, 
while no correlation was found between smoking and breast cancer. Exposure to ionizing radiation, 
regardless of the source, increases probability of breast cancer, especially during puberty [2,3]. 
1.1.2 Epidemiology of breast cancer  
Various malignancies account for over 15 million new cancer cases worldwide, with breast cancer 
being the second most common cancer globally with a 25 % prevalence, and the leading 
malignancy in women with over 1.5 million new cases yearly [6]. Breast cancer accounts for over 
a half million deaths yearly, and has the second highest mortality rate after lung cancer. Disease 
incidence grows yearly, as an alarming rate of 3.2 million new cases per year are predicted by the 
year 2050. Interestingly, incidence rates were much higher in developed countries than in less 
developed (71.7 versus 29.3 per 100,000), while mortality rate showed an opposite trend (17.1 
versus 11.8 per 100,000). Higher incidence can be correlated with modern upbeat and unhealthy 
lifestyles (less physical activity, high stress, bad nutrition, late pregnancy, etc.) in developed 
countries, while lower mortally with better health systems, prevention screenings and modern 
diagnostic methods [7]. Unfortunately, due to poor awareness, limited resources and unsuitable 
care undeveloped countries have almost a 20 % higher mortality rate than developed countries. 
[6,7].  Timely detection is related to the socio-economic status, as advanced disease detection is 
more common for less privileged areas [6]. The advancement in breast cancer diagnosis treatment 
and disease management has led to a yearly decline in disease mortality in the European Union 
(EU). A 15 % decline was observed in the period from 2002 (17.9/100,000) to 2012 
(15.2/100,000), while an additional 10 % is expected by the year 2020. Statistics for 2012 rank 
Slovenia above average in disease mortality (16.54 versus 15.19 per 100,000) among EU countries 
[8]. A novel epidemiology report (July, 2019) from the Cancer Registry of the Republic of 
Slovenia has reported breast cancer to be the most common malignancy in Slovenian women with 
20.4 % of all cancers in the 2012-2016 interval [9]. The average incidence in the same time period 
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was 1334 newly diagnosed patients yearly, while the average number of females living with the 
disease (prevalence) was 17316 [9].  
1.1.3 Breast cancer therapy  
The first step following a positive diagnosis of nonmetastatic breast cancer is the surgical removal 
of cancerous tissue [1,2]. Surgical sampling or removal of axillary lymph nodes is also a common 
accompanying procedure to remove cancer cells and prevent possible cancer metastases [1]. Pre-
surgical breast and lymph biopsies give important histological diagnosis, which helps surgeons in 
determining the course of the surgical procedure. The two most common procedures are breast 
mastectomy (removing of the entire breast, chest wall and all axillary lymph nodes) or breast 
conservation surgery (surgically removing as much cancerous tissue as possible while leaving the 
breast tissue and lymph nodes intact) [1,2]. Post-surgical therapy continues with 5-6 weeks of 
radiotherapy. Radiotherapy uses high-energy X-rays to destroy cancer cells that may have been 
left in the surrounding surgical area [2]. Radiotherapy targeting depends on the surgical procedure, 
as it can target breast tissue, chest wall (mastectomy) or lymph nodes. Post-surgical radiotherapy 
has shown to lower cancer recurrences probability by half [1].  
Unfortunately, there is still no available therapy for treating metastasizing breast cancer. Once 
metastases are confirmed, the main goal is prolonging the patient’s life and providing relief from  
symptoms through palliative treatment using system therapy or surgical and radiation treatments 
[1]. 
1.1.4 System therapy for non-metastatic breast cancer  
The two main molecular targets in system therapy are estrogen receptors (ER) and the human 
epidermal growth factor 2 receptor (HER2) [1-3]. Appropriate system therapy is determined by 
pathological staining for subtype specific molecular markers. System therapy can be preoperative 
(neoadjuvant), postoperative (adjuvant) or administered constantly during the course of 
malignancy [1]. 
1.1.4.1 Hormone positive (HR+) subtype  
The most common breast cancer subtype is the HR+, with a 60-70 % prevalence [1]. ER are steroid 
receptors that bind various endogenous (estradiol, estrone, estriol, estetrol) and exogenous 
estrogens or mimetics [10].  Two types of receptors have been identified, ERα and ERβ, with 
breast cancer oncogenesis being mediated only by ERα [9,10]. The molecular mechanism behind 
estrogen oncogenesis is based on gene transcription post ligand binding. ERs act as a transcription 
factor, which post ligand binding forms dimers, translocates into the nucleus and binds to DNA. 
ER regulated gene expression promotes cancer cell proliferation and cell viability [11]. 
Standard HR system therapy consists of ovarian suppressors (OS), aromatase inhibitors (AIs) and 
selective estrogen receptor modulators (SERMs). OS is based on consuming an oral antiestrogen 
drug in a time span of 5 years to lower estrogen levels, which has shown to decrease mortality 
rates and recurrence by 25 % [1,10]. Drugs such as leuprolide acetate or goserelin, are used in 
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suppressing gonadotropin-releasing hormone [1]. Biosynthesis of estrogens is a multistep 
transformational process in which cholesterol is converted to final products progestogens and 
androgens. This conversion process is catalyzed by the enzyme aromatase, which is the main target 
of inhibition. Inhibiting enzyme activity lowers estrogen concentrations. Two types of inhibitors 
exist; Type I, which are based on steroidal compounds and bind permanently to the enzyme, and 
type II, which are nonsteroidal compounds that bind reversibly [11]. The most commonly used AI 
are letrozole, anastrozole and exemestane [1,10]. Inhibiting enzyme activity can lead to common 
side effects such as hot flashes and arthralgias (joint stiffness), while also increasing the risk of 
developing osteoporosis [1]. SREMs are synthetic exogenous compounds that bind to ER with 
high affinity, and block estrogen binding, consequently inhibiting ER-mediated gene expression 
[11]. Since successfully passing the clinical trials back in the 1970’s, tamoxifen (TAM) has been 
widely used in treating ER+ breast cancer in pre and postmenopausal women. TAM is a 
nonsteroidal competitive ER antagonist that has receptor-binding ability in the nanomolar scale, 
similar to 7-β-estradiol [12]. Consuming TAM over a 5-year span reduces the recurrence rate by 
almost 50 %. The most common side effect of TAM are hot flashes, while in uncommon cases 
TAM can increase the risk of developing uterine cancer and thromboembolic diseases. 
ER receptor expression is commonly accompanied by progesterone receptor (PR) expression. 
While PR are used as biomarkers for staining HR breast cancer, they are not therapeutic targets as 
are ER [1].  
1.1.4.2 HER2+ positive subtype  
The second most common subtype is HER2+, in which the receptor is amplified or overexpressed. 
The following subtype holds an approximate 20-30 %  prevalence amongst breast cancers [1]. In 
comparison with ER+ subtype, HER2+ is connected with poorer prognosis, as it is more 
aggressive, and shows higher mortality and recurrence risks. HER2 is a member of the epidermal 
growth factor (EGF) family (HER 1-4), a group of transmembrane tyrosine-kinase receptors that 
bind the EGF. Upon ligand binding, the receptors undergo dimerization, which activates kinase 
activity and triggers a signal cascade. The EGF family is involved in cellular processes such as 
proliferation, differentiation and cell survival, being therefore often overexpressed in various 
cancers.  Interestingly, as HER2 is a sole member of the EGF family that lacks known ligands, the 
mode of action is believed to be ligand-independent dimerization with other members of the EGF 
family [13].  
Back in the 1990’s a humanized monoclonal antibody that targets the extracellular domain of 
HER2, named trastuzumab (brand name Herceptin (HER)), was developed [1]. This was 
considered a breakthrough in treating HER2+ subtype, which showed very poor prognosis prior to 
trastuzumab development due to lack of available system therapy [1,12]. The exact mode of action, 
post antibody receptor binding is still not fully understood, but is believed to promote apoptosis 
(PI3K/Akt inhibition, DNA repair inhibition) and cell cycle arrest (Increased P27, decreased cyclin 
D1 and CDK-2 levels) [13]. The most common side effects are sensory neuropathy and weakness, 
while in rare cases it can increase the risk of developing congestive heart failure [1,12]. 
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1.1.4.3 Triple-negative breast cancer subtype  
The third known subtype is triple-negative breast cancer (TNBC), least prevailed type, with an 
occurrence of 15-20 %. In comparison with ER+ and HER2+ subtypes, TNBC lacks molecular 
marker expression, which hinders diseases suppression, therefore making it the most aggressive 
phenotype with poor prognosis. TNBC have a 4-fold higher probability of developing distant 
metastasis in comparison to other subtypes. Hormonal and HER2 target therapies are shown to be 
ineffective in treating TNBC. TNBC can further be classified into 6 subtypes, which differ from 
one another in gene expression profiles and disease prognosis.  
Adjuvant or neoadjuvant chemotherapy in combination with radiotherapy is the standard treatment 
in TNBC. Unfortunately, there are no fixed guidelines in chemotherapy load management as it 
depends solely on disease and patient-related factors, such as: age, menopausal status, 
psychological status, previous therapies, disease control, etc. In the past decade, the most used 
therapy against TNBC is based on combination chemotherapy with taxanes (Taxol, Ixabepilone) 
and anthracylclines (doxorubicin, epirubicin). Taxanes function as microtubule stabilizers that 
inhibit cell division, while anthracylclines function as intercalating agents that prevent gene 
transcription.  
Platinum agents, such as cisplatin (CIS) are one of the first discovered chemotherapeutics with 
clinical usage dating back to the late 1970’s. CIS inhibits cell division by forming DNA crosslinks 
which prevent replication fork formation, and lead to double-strand DNA breaks. Cancer cells are 
unable to successfully fix this DNA breaks, as repair mechanisms are often mutated in cancer.  
Identifying TNBC molecular markers is crucial in future treatment development, with some 
potential targets explored, such as; Wnt/β-catenin, Notch, Hedgehog, JAK2 and BRCA-mediated 
pathways [14].  
1.1.5 Male breast cancer  
Breast cancer does not solely affect women, as male breast cancer (MBC) accounts for 
approximately 1 % of all breast cancers. Due to low prevalence, MBC is fairly unexplored in 
comparison to female breast cancer. Some risk factors have been identified; genetic (more frequent 
BRC2 mutations), age (average diagnosis after age 70), endocrine factors (exogenous estrogens, 
testicular dysfunction), occupational hazards, radiation exposure and lifestyle factors (alcohol, 
obesity). Diagnosis and treatment of MBC is mainly the same as in female cases; mammography, 
surgery, radiotherapy and appropriate system therapy. The majority of MBC are ER+, for which 
endocrine therapy (AI, TAM) is administered. MBC is often overlooked and diagnosed in late 
stages (III-IV), which leads to poor prognosis [15].   
1.2 Endocannabinoid system  
The endocannabinoid system (ECS) is composed of cannabinoid receptors (CBs), endogenous 
cannabinoids and enzymes involved in their synthetic and degradative pathways. Thus far, two 
types of receptors have been identified; cannabinoid receptor type 1 (CB1) and cannabinoid 
receptor type 2 (CB2). Both receptors are receptors similar to G protein-coupled receptors (GPCR), 
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which are involved in various cellular physiology and cognitive processes [16]. The vanilloid 
receptor TRPV1 (transient receptor potential cation channel subfamily V member 1) and GPR55 
(G protein-coupled receptor 55), are often called cannabinoid receptor type 3 (CB3), and are 
believed to be involved in the ECS [15,16]. Various endogenous and  exogenous 
phytocannabinoids, the most reported THC and others, as well as synthetic receptor ligands have 
been identified as binding to CBs [16]. Due to their involvement in pathologies, while also having 
therapeutic potential for many conditions, the ECS as a therapeutic target has been a hot research 
topic in the past few years [18]. 
1.2.1 Cannabinoid receptor type 1 
As mentioned above, CB1 is a GPCR associated receptor, which was discovered back in the 1990’s 
as the first receptor of the ECS [19]. The receptor 472 amino acid long is encoded by the gene 
CNR1, which is referred to as canonical sequence, due to identification of two new CB1 splice 
variants [19,20]. Apart from having shorter amino acid sequences (CB1a 411 amino acids, CB1b 
439 amino acids), both isoforms are present in low abundance, and are believed to function outside 
the cannabinoid pharmacology. In comparison with CB1, both isoforms have altered binding 
ability for cannabinoids, with distant expression patterns and functions; highly expressed in the β-
cells and hepatocytes and involved in metabolic functions [19,21]. Canonical CB1 expression and 
function is best described in the central and peripheral nervous system. CB1 expression is not 
solely limited to the nervous system, as positive expression is present in other peripheral tissues, 
such as: cardiovascular, gastrointestinal, immune system, skeletal muscle, pancreatic, fat tissue 
etc. The function of CB1 in the majority of aforementioned tissues is still under investigation [19]. 
Apart from widespread localization across the body, CB1 receptor is shown to have different 
localization sites on the cellular level. CB1 is dominantly localized on the plasma membrane, but 
further research has shown that internalized (endosome) and intracellularly (mitochondria, 
lysosome) located receptors are also present. These subpopulations, are shown to have diverse 
functions from membrane-bound CB1. CB1 is a Gi/o type of GPCR (Figure 1a), which means that 
once activated it inhibits adenylyl cyclase (AC) activity and blocks the accompanying pathway of 
cyclic adenosine monophosphate (cAMP) formation and protein kinase A activation (PKA) 
(Figure 1b). Another inhibitory function of CB1 is the ability to suppress influx of Ca2+ ions by 
closing voltage gated calcium channels. CB1 mechanism is not solely limited to inhibiting signal 
pathways; the receptor is shown to activate several proteins from the mitogen-activated protein 
kinases (MAPK) family and phosphoinositide-3-kinase/ protein kinase B (PI3K/Akt) pathway. 
CB1 regulated signal pathways can either promote cell survival or death, as fate depends on the 
type of bound ligand and the subcellular environment. Due to the widespread expression and 
overlap with various important and frequent signal pathways, it is fair to assume that the ECS and 
CB1 are important in regulating various physiological roles, while also being associated with many 
pathologies. CB1 regulates physiological processes such as: appetite, learning, memory, pain 
regulation, energy metabolism, reproductive and cardiovascular system functions. Interestingly, 
CB1 levels are shown to vary in pathological conditions, as the presence or absence of CB1 is 
pathology specific, and can have either positive or negative effects on treatment. Some pathologies 
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connected to CB1 are: anxiety, depression, schizophrenia, stroke, neurodegeneration, multiple 
sclerosis, epilepsy, glaucoma and cancer [21]. 
 
Figure 1. CB1 crystal structure and mode of action. a) Structure of CB1 in complex with a G-protein. Seven 
membrane α-helices are shown in dark grey, with transmembrane domains colored in cyan. Cytoplasmic Gα domain 
is shown in pink, Gβ in yellow, Gγ in green. PDB accession code: 6N4B. b) CB1 signaling pathway. (AC) adenylyl 
cyclase, (Akt) protein kinase B, (Ca2+) Calcium ion, (cAMP) cyclic adenosine monophosphate,  
(MAPK) mitogen-activated protein kinases, (PI3K) phosphoinositide-3-kinase, (PKA) protein kinase A activation. 
Adapted from [21]. 
1.2.2 Cannabinoid receptor type 2 
The second discovered receptor of the ECS was CB2, also a GPCR associated receptor with two 
known isoforms, which is coded by the gene CNR2. In comparison to CNR1, CB2 gene is shorter 
(360 amino acids) and possess only 44 % sequence homology [21]. Isoform CB2A is found in the 
testis and lower brain regions, while CB2B is more present in peripheral tissue, such as the spleen 
[23]. Due to their abundance in the immune system, CB2 was discovered in macrophage cells 
isolated from the spleen [21]. Human leukocytes, such as B ant T-cells, basophiles, eosinophils, 
mast cells, macrophages, NK cells and neutrophils have all shown to express CB2 [24]. Apart from 
being widely present across the immune system, CB2 can be found in peripheral tissue 
(gastrointestinal tract, cardiovascular and reproductive system, adipose tissue, liver) with moderate 
expression [21]. It was firstly believed that CB2 expression is limited solely to the periphery, but 
novel research has proven otherwise, as CB2 presence has been found in the brain, with lower 
expression intensity. The main function of CB2 is to trigger pro-inflammatory or anti-
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inflammatory effects in immune cells, depending on the interacting ligand, while neural CB2 
expression is connected to nociception, drug addiction and neuroinflammation. Even though both 
CBs are GPCR (Figure 2a), CB1 signal pathway is much more clarified in comparison to CB2 
[20,23]. CB2 was also shown to be a a Gi/o type of GPCR, which means inhibition of AC activity 
and lowering cAMP levels, while being unable to block voltage gated ion channels (Figure 2b). 
CB2, just as CB1, is able to activate proteins of the MAPK and PI3K family, and their respective 
pathways. The receptor is shown to be involved in calcium metabolism by activating the 
phospholipase C (PLC)/inositol 1,4,5-triphosphate (IP3) pathway, which consequently increases 
intracellular and mitochondrial Ca2+ levels (Figure 2b)  [24].  
 
Figure 2. CB2 crystal structure and mode of action. a) Structure of CB2 in complex with a G-protein. Seven 
membrane α-helices are shown in dark grey, with transmembrane domains colored in cyan. The structures of G-protein 
cytoplasmic domains is unknown [25]. Fusion protein T4-lysozyme (pink) facilitated crystallization [25]. PDB 
accession code: 5ZTY. b) CB2 signal pathway. (AC) adenylyl cyclase, (Akt) protein kinase B, (Ca2+) calcium ion, 
(cAMP) cyclic adenosine monophosphate, (ER) endoplasmic reticulum, (IP3) inositol 1,4,5-triphosphate, (MAPK) 
mitogen-activated protein kinases, (PI3K) phosphoinositide-3-kinase, (PLC) phospholipase C, (PIP2) 
phosphatidylinositol 4,5-bisphosphate, (PKA) protein kinase A activation. Adapted from [23]. 
1.2.3 Cannabinoids 
Three types of compounds exist which can trigger the activation of the ECS system: 
endocannabinoids, phytocannabinoids and synthetic cannabinoids (Figure 3). 
The first type of cannabinoids are endocannabinoids, endogenously synthesized signaling lipid 
molecules that possess the ability to bind to CBs. Anandamide (AEA) and 2-arachidonoyl glycerol 
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(2-AG) were the first discovered endocannabinoids and are the ones best characterized up to date. 
Even though AEA and 2-AG are members of the same lipid family, they possess distinct traits 
from their mode of action, synthesis and degradation. Both molecules act as agonist for CBs, but 
with deviation in binding affinity, as AEA possess high affinity for both CBs, while 2-AG shows 
low affinity to CB1 and very low to CB2. Apart from binding affinity, endocannabinoids possess 
diverse routes of synthesis and degradation. Other lipid molecules, such as 2-Arachidonyl glyceryl 
ether (2-AGE), N-Arachidonoyl dopamine (NADA) and virodhamine (OAE) have been identified 
as endocannabinoids, but their mode of action has still not been well characterized [16].  
The second class of cannabinoids are phytocannabinoids, aromatic hydrocarbons found 
predominantly in the Cannabis sativa L. plant, with over 120 cannabinoids identified and isolated 
up to date. The majority of phytocannabinoids possess a similar structural base; dibenzopyran ring 
and a hydrophobic alkyl chain (Figure 3). Even though phytocannabinoids have similar structural 
traits, they show diverse affinities for CBs binding. The most abundant phytocannabinoid is Δ9- 
Tetrahydrocannabinol (Δ9-THC), psychoactive compound, which is often connected with 
marijuana consumption. Δ9-THC is shown to act as a partial agonist for both CBs. Due to being a 
partial agonist, Δ9-THC displays a mixed agonist-antagonist mode of action, varying between cell 
types. In addition, factors such as receptor expression and presence of endocannabinoids or full 
agonists determine Δ9-THC mode of action [26]. Δ9-THC is shown to have activity outside the 
ECS. Another abundant phytocannabinoid is Cannabidiol (CBD), which has become interesting in 
the past few years due to its potential therapeutic traits. CBD shows weak CBs antagonistic effect, 
while also negative allosteric modulation of Δ9-THC and 2-AG. In comparison to Δ9-THC, CBD 
lacks psychoactive side effects. Other high abundant members of the phytocannabinoid family are 
cannabinol (CBN), cannabigerol (CBG), cannabichromene (CBC) and Δ8-tetrahydrocannabinol 
(Δ8-THC), with the latter possessing psychoactive traits, similar to Δ9-THC [26]. Novel 
phytocannabinoids have been identified outside the cannabis family, in Helichrysum 
umbraculigerum, Echinacea and Radula species [27].  
The third types of cannabinoids are synthetic cannabinoids, which are laboratory-synthesized 
mimetics of phyto and endocannabinoids. When the field of synthetic cannabinoids started back 
in the 1970’s, its goal was to develop synthetic cannabinoids for experimental and therapeutic 
purposes. Today, synthetic cannabinoids show a growing problem, as over 560 synthetic 
psychoactive compounds have been identified for recreational use. This compounds are in general 
poorly characterized (pharmacology, composition), which makes them potentially harmful  [28].  
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Figure 3. Endocannabinoids, phytocannabinoids and synthetic cannabinoids. Molecular structures taken from 
Wikipedia, an open source encyclopedia (https://www.wikipedia.org). Legend: Anandamide (AEA), 2-arachidonoyl 
glycerol (2AG), virodhamine (OAE), 2-Arachidonyl glyceryl ether (2-AGE), Δ9- Tetrahydrocannabinol (Δ9-THC), 
cannabidiol (CBD), cannabinol (CBN), cannabigerol (CBG). 
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1.2.4 Therapeutic potential of the endocannabinoid system 
The correlation between the ECS and its potential as a therapeutic target was firstly reported over 
35 years ago. A handful of pathologies have shown to alter the ECS, with varying levels of CBs 
expression and endocannabinoid levels. Unfortunately, there is no pattern of expression, as in some 
cases CBs are overexpressed and connected with poor disease prognosis, while other pathologies 
are shown to lower ECS activity. 
Today, high quality evidence exists on the positive effects of cannabinoids in treating neuropathic 
pain, multiple sclerosis (MS), epilepsy and cancer (palliative treatment). A handful of cannabinoid 
based drugs have been approved in treatment of the above listed pathologies (Table 1) [18]. 
Table 1. List of cannabinoids and their approved therapeutic applications. [18] Legend: Acquired immune 
deficiency syndrome (AIDS), cannabidiol (CBD), multiple sclerosis (MS), Δ9-Tetrahydrocannabinol (Δ9-THC). 
Cannabinoid Brand name Therapeutic applications 
Nabilone 
Δ9-THC analogue 
Cesamet® Suppression of chemotherapy 
induced side effects Canemes® 
Dronabinol 
(-)-trans-Δ9-THC 
Marinol® Suppression of chemotherapy 
induced side effects, AIDS related 
anorexia 
Syndros® 
Pure CBD Epidiolex® 
Suppression of epilepsy induced 
seizures 
Nabiximols 
Δ9-THC:CBD 1:1 ratio 
Sativex® MS pain relief, spasticity control 
 
The potential of cannabinoids is being further explored, and tested in undergoing clinical trials on 
various neurological disorders (Parkinson’s, Alzheimer’s, Huntington’s), psychiatric disorders 
(Post-Traumatic Stress Disorder (PTSD), Tourette syndrome, anxiety disorders), glaucoma and 
cancers (brain, breast, prostate, bone, skin, cervix, pancreas, leukemia) [18,29].  
Apart from palliative cancer treatment, various in vivo and in vitro experiments have shown that 
cannabinoids possess antitumor effects by targeting cellular processes such as cell cycle, 
proliferation, death, migration/invasion and angiogenesis/metastasis. The exact involvement of the 
ECS in cancer is still not fully clear, due to the complex interweaving of several signal pathways. 
Antiproliferation and cycle arrest are believed to be connected with the inhibition of adenylate 
cyclase activity, and consequently PKA. Multiple pathways are connected to programed cell death; 
MAPK pathway activation, PI3K-AKT pathway suppression or CBs mediated ceramide synthesis 
with consequent activation of Raf-1-MEK-ERK pathway. Tumor progression is inhibited on 
several points; FAK–Src–RhoA pathway inhibition, programed cell death/cell cycle arrest of 
endothelial cells, suppression of matrix metalloproteinases activity. Elevation of endocannabinoid 
levels are shown to suppress tumor growth, inhibit epithelial-mesenchymal transition and trigger 
antiproliferative response [30]. 
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1.2.5 Endocannabinoid system in breast cancer 
Positive expression of CBs in breast cancer cell lines has been identified, with an overall higher 
expression levels of CB2 in comparison to CB1 [31]. The extensive research on cannabinoid anti-
tumorigenic effects in breast cancer cell lines is summarized in Table 2.  
Interestingly, 91 % of HER2+ breast cancer phenotype is shown to overexpress CB2, suggesting 
a possible connection between receptor expression, tumor aggressiveness and poor prognosis [32]. 
CB2 is believed to enhance tumor aggressiveness by activation of PI3K/Akt or ERK/MAPK signal 
pathways. HER2+ mice model showed promising results with THC or synthetic JWH-133 
treatment. The tested cannabinoids are believed to lower tumor aggressiveness by blocking 
PI3K/Akt/mTOR signal pathway, while also achieving lower expression levels of matrix 
metalloproteinase 2 (MMP2) and vascular endothelial growth factor (VEGF), consequently 
lowering tumor metastatic and angiogenetic potential [31].  
An interplay between the ECS and ER is believed to exist. TAM, a selective estrogen receptor 
modulator is able to trigger cytotoxic effects in hormone negative phenotypes. The exact 
mechanism is poorly understood, but novel research showed that TAM has the ability of moderate 
affinity binding to CBs, while triggering inverse agonist effects, resulting in lower G-Protein 
activity and increasing intracellular cAMP levels. These results indicate that CBs could mediate 
ER independent TAM cytotoxicity. This interplay could potentially be exploited in developing a 
novel selective and non-toxic TAM based therapeutic, which acts by triggering the ECS and CBs 
[33]. Pharmacological characteristics for CBs affinity have been tested with various TAM isomers 
and SREM [33,34].  
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Table 2. Cannabinoid effects in breast cancer cell lines. (AEA) Anandamide, (2AG) 2-arachidonoyl glycerol, (Akt) 
protein kinase B, (BID) BH3 interacting-domain death agonist, (EGFR) epidermal growth factor receptor, (Cdc2) 
cyclin-dependent kinase 2, (ID-1) inhibitor of DNA binding 1, (MMPs) matrix metalloproteinases, (mTOR) 
mechanistic target of rapamycin, (NGF) nerve growth factor, (PPARγ) peroxisome proliferator-activated receptor γ, 
(ROS) reactive oxygen species, (Th1) T helper response, (Th2) Th2-associated cytokine, (Δ9-THC)  
Δ9-Tetrahydrocannabinol. ↑: Upregulation, ↓: Downregulation. Adapted from [31].  
Cannabinoid Cell line Cannabinoid effect Cellular response 
CBD 
MCF-7, ZR-75-1, T-47D, 
MDA-MB-231,MDA-
MB-468, SK-BR-3 
Antiproliferative effect • ↑ Resting G0 stage 
MDA-MB-231 
Cell death (Apoptosis, 
autophagy) 
• ↑ ROS, PPARγ  
• ↓ Akt, mTOR 
• Beclin 1 triggered 
autophagy  
ER+, ER-  
• ↑ Mitochondrial 
membrane permeability  
• BID translocation  
• ↑ Cytochrome C 
MDA-MB-231, MDA-
MB-436 
Metastasis inhibition • ↓ID-1 
SUM159, SCP2 
Inhibition of EGF-
mediated tumorigenic 
properties  
• Inhibition of EGFR, 
Akt, ERK, NF-κB 
↓ MMP 
THC 
EVSA-T, MDA-MB-231, 
MDA-MB-468, SKBR-3, 
MCF-7, T-47D 
Cell death (Apoptosis)  
• G2/M cell cycle arrest 
• ↓Cdc2 
• ↑ ROS 
MCF-7, MDA-MB-231 Anti-inflammatory effect  
• ↓Th1 response 
• ↑Th2 
• Inhibition of NF-κB, 
MAPK, JAK-STAT  
AEA 
- Antiproliferative effect 
• Modulation of 
PKA,MAPK 
• ↓ NGF, prolactin 
receptors 
EFM-19 Cell cycle arrest  
• Blocking of G1/S 
transition 
2-AG MCF-7, T-47D, EMG-19 Antiproliferative effect 
• Modulation of 
PKA,MAPK 
• ↓ NGF, prolactin 
receptors 
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2 AIMS AND HYPOTHESES   
The first aim of the thesis was to validate the specificity of two sets of antibodies against CB1 and 
CB2, while also determining the levels of expression of CBs in breast cancer cell lines. In hopes 
to quantitate and possibly localize the CBs receptors in the selected breast cancer cells, two sets of 
antibodies with different clonality were tested. With using western blot analysis to determine the 
specificity of selected antibodies and expression of CBs at the protein level, and 
immunocytochemistry for sub-cellular detection of CBs proteins we wanted to fully characterize 
the ECS in selected breast cancer cells. Determining the positive presence of CBs receptors in 
selected breast cancer cells is an essential first step in potentially exploiting the ECS in breast 
cancer treatment.  
The second aim was to determine the effect of cannabinoids on cell viability and its interaction 
with treatment response. We subjected breast cancer cells to cannabidiol (CBD) treatment in hopes 
of diminishing cell viability by exploiting the ECS. Combination of CBD with standard phenotype-
specific therapy (tamoxifen, cisplatin or herceptin) was tested with aim to enhance the effect of 
CBD on cell viability, determine potential drug-drug correlations and synergism.  
Treatment response to cannabinoids will be further analyzed in vitro as a possible novel 
therapeutic. Breast cancer patient tissue will be stained for CB1 and CB2 expression using selected 
antibodies.  
This research will be further developed within the research project conducted in collaboration 
between the Institute of Oncology (IO), the Faculty of Medicine (MF) and the National Institute 
of Biology (NIB). 
Based on our aims, we have tested two hypotheses:  
1. Selected breast cancer cell lines express various levels of CB receptor protein 
2. Cannabidiol (CBD) decreases the viability of breast cancer cells alone, and in combination with 
standard breast carcinoma cell subtype-specific therapy. 
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3 MATERIALS AND METHODS 
3.1 Breast cancer cell lines   
Immortal breast cancer cell lines MCF-7, MDA-MB-231, MDA-MB-361, SK-BR-3 and T-47D 
were used. All cell lines are adherent and of human origin, but differ in characteristics, such as 
tumor type of origin and receptor expression (Table 3). With the following selection of cells lines, 
we covered the spectrum of hormone receptor expression in breast cancer cells. Hormone receptor 
expression values were obtained from the doctoral dissertation of Nina Trošt [36]. As control cell 
lines, we used MCF-10A and glioma cells. MCF-10A are non-tumorigenic, human adherent cells, 
isolated from the breast of a patient with fibrocystic disease. Glioma cells were acquired from the 
NIB, which has isolated the cells from the tumor tissue and successfully cultured them.  
Table 3. Breast cancer cell line characteristics. Estrogen receptor (ER), Progesterone receptor (PR), the human 
epidermal growth factor 2 receptor (HER2). + positive for receptor expression, - negative for receptor expression. 
Cell line Origin Tumor type Subtype Culture Properties Status 
MCF-7 
Human 
Invasive ductal 
carcinoma 
Luminal A 
Adherent 
ER+, PR+, HER- 
T-47D ER+, PR+, HER- 
MDA-MB-361 
Adenocarcinoma 
Luminal B ER+, PR-, HER- 
MDA-MB-231 
Basal 
B/claudin low 
ER-, PR-, HER- 
SK-BR-3 
HER2 
overexpression 
subtype 
ER-, PR-, HER+ 
 
3.1.1 CBs mRNA expression levels using proteomic databases 
We used the available literature and database as starting reference points for receptor expression 
in selected cell lines. Database values were obtained using Cancer Cell Line Encyclopedia (CCLE, 
https://www.ebi.ac.uk/gxa/experiments/E-MTAB-2770/Results), an open database, which is a 
component of the Expression Atlas of the European Bioinformatics Institute (EBI) and supported 
by Elixir. The Expression Atlas contains information about gene and protein expression, RNA 
abundancy and localization, and alterations in gene expression in disease state. All RNA-Seq and 
microarray data are manually curated by specialists. All data are presented as easily-interpretable 
heatmap visualizations. CCLE uses RNA-seq, a new generation sequencing method to determine 
expression levels of mRNA in cancer cells. CCLE has RNA-seq data of 934 human cancer cell 
lines, including the selected breast cancer cell lines studied in this thesis. The search query was 
modified; CNR1 and CNR2 genes were selected, detectable expression values were lowered to 
0.0, data unit was set on transcript per million (TPM) and selected breast cancer cell lines were 
chosen from the pool of 934 known human cancer cell lines. 
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3.1.2 Cell culturing 
Cell lines were cultured in growth media recommended by ATCC [37]. To complete the growth 
medium, fetal bovine serum (FBS) and antibiotic mixture Pen-Strep (P/S) were added to each base 
medium (Table 4). Cell line T-47D showed lack of adhesion in ATCC-recommended RPMI-1640 
medium, even after additional insulin was added. Based on literature recommendations, we 
substituted RPMI-1640 with DMEM, which resulted in successful adhesion and growth. Defrosted 
cell lines were cultivated in T-25 cell culture flasks with 5 mL of medium. Cell medium was 
changed on a regular basis, approximately every two days. All work was done under sterile 
conditions in the cell laminar. Cells were stored in a CO2 cell incubator at 37 °C. Growth and 
adhesion was observed under the optical microscope. After the cells reached appropriate 
confluency, they were grafted in larger T-75 cell culture flasks. The laboratory equipment and 
chemicals used for cell culturing are shown in Table 4. and Table 5.  
Table 4. Breast cancer cell line growth medium. Fetal bovine serum (FBS), Pen-Strep (P/S). 
Cell line Medium FBS P/S 
MCF-7 
DMEM 10 % 
1 % 
T-47D 
MDA-MB-361 Leibovitz's L-15 / 
MDA-MB-231 DMEM/F12 
10 % 
SK-BR-3 McCoy’s 5A 
  
Table 5. Cell laboratory equipment  
Laboratory equipment Manufacturer 
Cell incubator Sanyo CO2 incubator 
Cell laminar Iskra PIO, C-MaxPro3-130 
Optical microscope Nicon Eclipse TS100 
T-25 cell culture flask Corning, #430168 
T-75 cell culture flask  Corning, #430641U 
Pipette gun Thermo Scientific, S1 Pipette Filler 
Sterile pipettes (5mL, 10mL, 25mL, 50mL) Corning, #4487, #4488 
 
Table 6. Chemicals for cell culturing and grafting. Fetal bovine serum (FBS), Pen-Strep (P/S). 
Chemicals Manufacturer 
DMEM/High glucose medium GE Healthcare Life Sciences, #SH30022.01 
Leibovitz's L-15 medium Gibco, #11415-049 
DMEM/F12 medium  Gibco, #11320-033 
McCoy’s 5A medium  ATCC, #63918465 
FBS Gibco, #10500-064 
P/S Sigma, #P0781 
Trypsin (0.25 % Trypsin-EDTA 1x) Gibco, #25200-056 
DPBS (10x) Gibco, #14200-067 
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After reaching adequate confluency in T-25 cell culture flasks, cell lines were grafted using the 
serine protease trypsin, which causes detachment of cells from the flask. Excess medium was 
removed, cells were washed in 5 mL 1 % Phosphate-buffered saline (PBS) solution. PBS buffer 
was removed, and 1 mL of 0.25 % Trypsin-EDTA solution was added. Cells were stored in the 
incubator for approximately 1-2 minutes (min) (depending on the cell line), after which cell 
detachment was observed under the optical microscope. To suppress further cell damage by 
trypsin, we added equal volume of growth medium. The cell line solution was transferred to bigger 
T-75 cell culture flasks. Additional medium was added to a final volume of 15 mL. All work was 
done under sterile conditions in the cell laminar. Cells were stored in a CO2 cell incubator at 37°C. 
After achieving confluency, cell lines were used for creating protein pellets for WB analysis, and 
immunocytochemistry (ICC) slides or were stored (frozen). The chemicals used for cell grafting 
are shown in Table 6. 
3.1.3 Cell pellet  
Cell pellets, were prepared with the aim to isolate proteins for WB method. After trypsinization of 
confluent cells and growth medium addition, the cell line mixture was centrifuged for 3 min at  
635 relative centrifugal force (G). The supernatant (medium + trypsin) was removed, the pellet 
was resuspended in 1 mL of 1 % PBS, and transferred in a 1.5 mL tube. The solution was once 
more centrifuged for 3 min at 635 G in a microcentrifuge, after which the supernatant (PBS) was 
removed, and the pellet was stored at -20 °C until needed. The laboratory equipment for pellet 
formation is shown in Table 7. 
Table 7. Laboratory equipment for protein pellet formation  
Laboratory equipment Manufacturer 
Centrifuge  Tehtnica Železniki, PLC-322 
Microcentrifuge   Eppendorf MiniSpin, #022620100 
 
3.1.4 Immunocytochemistry slides  
For the ICC method, slides with adherent cells were prepared. After trypsinization of confluent 
cells and growth medium addition, approximately 1 mL of cell line suspension was added on the 
clean slides that were placed in sterile plastic petri dishes. The sterile dishes acted as a flask, in 
which cells grow and adhered for 24 hours (h). Cells were stored in a CO2 cell incubator at 37 °C. 
Successful adhesion was confirmed under the optical microscope. If needed, additional medium 
was added to the dishes. After successful adhesion, the slides were washed with 1 % PBS, and left 
for 3 min in 4 % formaldehyde to fix the cells on to the slides. This step should be taken with 
caution, as excessive formaldehyde exposure can lead to cell death. The fixed slides were stored 
at -20 °C until needed. The laboratory equipment and chemicals used for ICC slide preparation are 
shown in Table 8 and Table 9. 
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Table 8. Laboratory equipment for preparation of ICC slides  
Laboratory equipment Manufacturer 
Slides  ThermoScientific, # J3800AMNZ 
Petri dishes  Corning, #70165-60 
 
Table 9. Chemical for preparation of ICC slides  
Chemical Manufacturer 
4 % formaldehyde Merck, #100496 
 
3.1.5 Cell freezing 
Cell lines were stored by frozen, until needed for tests of cell treatment and viability. After 
trypsinization of confluent cells and growth medium addition, the cell line mixture was centrifuged 
for 3 min at 635 G. The supernatant (medium + trypsin) was removed and the pellet was 
resuspended in the freezing medium which consisted of growth medium, 10 % FBS and 10 % 
dimethyl sulfoxide (DMSO). The suspension was transferred in cryogenic vials, and stored at  
-80 °C in the freezer. The laboratory equipment and chemicals used for cell freezing are shown in 
Table 10 and Table 11. 
Table 10. Laboratory equipment for cell freezing   
Laboratory equipment Manufacturer 
Cryogenic vials  Corning, #430499 
 
Table 11. Chemical for cell freezing   
Chemical Manufacturer 
DMSO Honeywell, #41640-1L 
3.2 Protein Isolation 
3.2.1 Protein isolation from cell pellets 
Proteins were isolated from stored cell pellets of breast cancer cell lines using RIPA extraction and 
lysis buffer, while adverse protease and phosphatase effects were inhibited using a cocktail of 
inhibitors. Cell pellets were taken out of storage (-20°C), and were left to defrost on ice. Prior to 
use, RIPA isolation buffer solution was mixed with diluted (100x) EDTA, protease and 
phosphatase inhibitor (Table 13). To remove excess PBS, protein pellets were centrifuged for  
1 min at 13000 x G at 4°C. Depending on pellet size, 50-150 µL of isolation solution was added 
to each pellet, and resuspended with vortexing. The pellet solution was left to incubate on ice for  
15 min. Post-incubation, the solution was centrifuged for 15 min at 14000 x G and 4°C. The 
supernatant was transferred to a new tube and was ready for measuring the protein concentration 
or was stored at -20°C for future usage. As some cell lines failed to form distinct differences 
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between pellet and supernatant (turbid, viscose solution), to maximize our yield, the second series 
of isolation was sonicated (amplitude 40 %, cycle 3.5 seconds (s)) prior to centrifugation. The 
pellets were sonicated (15 s) and incubated on ice (15 s) for two cycles. The laboratory equipment 
and chemicals used for protein isolation are shown in Table 12 and Table 13.  
Table 12. Laboratory equipment for cell pellet protein isolation   
Laboratory equipment Manufacturer 
Centrifuge Eppendorf 5810R  
Ultrasonicator Roth UP100H 
 
Table 13. Chemicals for protein isolation 
Chemicals Manufacturer 
RIPA Lysis and Extraction Buffer (1x) Thermo Scientific, #89900 
Halt™ Protease Inhibitor Cocktail (100x) Thermo Scientific, #78430 
Halt™ Phosphatase Inhibitor Cocktail (100x) Thermo Scientific, #78420 
EDTA (100x) Thermo Scientific, #89900 
 
3.2.2 Bicinchoninic acid assay  
Bicinchoninic acid (BCA) assay kit was used for measuring the protein concentration in cell 
lysates. For calibration curve preparation, we used ascending set of BSA concentrations  
(125 µg/mL, 250 µg/mL, 500 µg/mL, 750 µg/mL, 1000 µg/mL, 1500 µg/mL, 2000 µg/mL,  
4000 µg/mL). Assay reagent and lysates were mixed in a 50:1 ratio, with 190 µL of assay reagent 
added to each microtiter plate well. Lysates was diluted in RIPA buffer and likewise added 10 µL 
to each well. All samples and standards were tested in duplicates, while average duplicate values 
were taken into account. Microtiter plates were gently shaken for 1 min and left to incubate at 
37°C for 30 min. Post incubation, absorbance (562 nm) was measured using a Synergy 
spectrophotometer. Protein concentration values were obtained by plotting absorbance values 
against the BSA standard value calibration curve. Diluted lysates were stored at -20°C for future 
use. The laboratory equipment and chemicals used for BCA assay are shown in Table 14 and Table 
15. 
Table 14. Laboratory equipment for BCA assay 
Laboratory equipment Manufacturer 
Spectrophotometer   Synergy 
96-well microtiter plate Thermo Scientific, #2101 
 
Table 15. Chemicals for BCA assay 
Chemicals Manufacturer 
Pierce™ BSA Protein Assay Kit Thermo Scientific, #23227 
Bovine Serum Albumin (BSA) Set Thermo Scientific, #23208 
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3.3 Western Blotting 
Denaturing WB method was used to determine the expression of CBs in breast cancer cell lines on 
a protein level. The method is based on electrophoresis separation of isolated proteins depending 
on their molecular weight, which are denatured prior to gel loading. Post separation, proteins were 
transferred to a polyvinylidene difluoride (PVDF) membrane. This transfer allows our proteins to 
be accessible for antibody detection. Prior to antibody staining, the membrane was blocked with 
non-fat dry milk to prevent unspecific antibody binding. The membrane was left to incubate 
overnight in primary antibody dilution. After rinsing the unbound primary antibodies, the 
membrane was incubated in secondary antibody dilution. Prior to detection, the membrane was 
washed. Final addition of chemiluminescent reagent enabled detection and visualization of our 
proteins. 
3.3.1 Polyacrylamide gel preparation 
A mixture of 10 % stacking and 5 % running gel solutions was prepared based on the recipe shown 
in Table 16. Polymerization chemicals (Ammonium persulfate (APS) and 
Tetramethylethylenediamine (TEMED) were added just before pouring gel solutions between 
plates, to prevent premature polymerization. We used a 1.5 mm spacer plate, which was assembled 
with a short plate in the casting frame, and both were placed in the casting stand before pouring 
the gel solution. Approximately 8 mL of 10 % stacking gel solution was pipetted between plates, 
and was left to polymerize for 20-30 min. Additional 500 µL of isopropanol was added on top of 
the stacking gel to remove possible air bubbles and to straighten out the gel line. After the stacking 
gel polymerized, isopropanol was removed using filter paper. The plates were filled to the top with 
2 mL of 5 % running gel. Afterwards, sample combs were carefully added. The stacking gel was 
left to polymerize for 10-15 min. Unused gels were wrapped in soaked (dH2O) paper towels, and 
stored in the refrigerator up to one week at 4°C. The laboratory equipment for gel preparation is 
shown in Table 19. 
Table 16. SDS-PAGE gel preparation. Recipe values adequate for 2 gels. Ammonium persulfate (APS), 
tetramethylethylenediamine (TEMED), sodium dodecyl sulfate (SDS). 
Chemical  10 % Stacking gel 5 % Running gel Manufacturer 
dH2O 9.56 mL 3.64 mL / 
1.5 M Tris-HCl, pH 8,8 4.98 mL / See Table 17 
1 M Tris-HCl, pH 6,8 / 625 µL See Table 18 
Rotiphorese Gel 40 
(37,5:1) 
4.98 mL 637.5 µL Roth, #T802.1 
10 % (w/v) SDS 199 µL 50 µL Sigma, #L3771 
10 % (w/v) APS  199 µL 50 µL Sigma, #A9164 
TEMED 8 µL 5 µL Sigma, #T9281 
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Table 17. Recipe for 1.5 M Tris-HCl.   
Chemicals Volume Manufacturer 
Trizma base 27.23 g Sigma, #T6066 
dH2O 80 mL / 
HCl Set up pH to 8.8 Sigma, #H1758 
dH2O Fill to final 150 mL / 
 
Table 18. Recipe for 1 M Tris-HCl.   
Chemicals Volume Manufacturer 
Trizma base 18.16 g Sigma, #T6066 
dH2O 60 mL / 
HCl Set up pH to 6.8 Sigma, #H1758 
dH2O Fill to final 100 mL / 
 
Table 19. Laboratory equipment for gel preparation 
Laboratory equipment Manufacturer 
1.5mm spacer plate 
BioRad, #1658035 
Short plate 
Casting frame 
Casting stands  
Sample comb 
 
3.3.2 Sample preparation and WB electrophoresis 
Cell lysates were removed from storage at -20°C, and were left to incubate on ice. Once the gel 
was fully polymerized, we started preparing protein samples. We mixed the loading buffer (6x) 
and 1,4-dithiothreitol (DTT) (10x) with the appropriate amount (µg) of cellular proteins, and if 
needed filled to the final loading volume with dH2O (Table 23). To achieve denaturation, proteins 
were incubated in the heating block for 10 min at 70°C. Gels were removed from the casting stands 
and frames, and were placed into the running module. Altogether was placed in the buffer tank, 
which was filled with electrophoresis buffer (1x) (Table 22). We carefully removed combs, washed 
gel wells and loaded sufficient volume of samples (10 µL) or Page Ruler protein standard (4 µL). 
The lid with power cables was mounted on the buffer tank, and was connected to the PowerPac 
HC power supply. We ran our electrophoresis for 15-20 min at 60 volts (V), so that our samples 
could travel throughout the stacking gel. Afterwards, we increased the voltage to 100 V, and left 
it to run for approximately 1-1:15 h, or until the lowest protein standard reached the end of the gel. 
The laboratory equipment and chemicals used for sample preparation and electrophoresis are 
shown in Table 20 and Table 21. 
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Table 20. Laboratory equipment for sample preparation and electrophoresis  
Laboratory equipment Manufacturer 
Running modules 
BioRad, # 1658035 
Buffer tank 
Lid with power cables 
PowerPac HC power supply 
CH-100 Heating Block BioSan, # BS-010410-BAI 
 
Table 21. Chemicals for sample preparation and electrophoresis. 1,4-Dithiothreitol (DTT) 
Chemicals Manufacturer 
Page Ruler protein standard Thermo Scientific, #26616 
DTT Roth, #6908 
Loading buffer NuPAGE (4x) Invitrogen, # NP0007 
Electrophoresis buffer See Table 22 
 
Table 22. WB electrophoresis buffer (1x). Sodium dodecyl sulfate (SDS). 
Chemicals Volume Manufacturer 
Trizma base 3.03 g Sigma, #T6066 
Glycine 14.41 g Sigma, # G8898 
SDS 1 g Sigma, # L3771 
dH2O Fill to final 1L / 
 
Table 23. Protein loading mixture: 20 µg of proteins obtained in a final 10 µL volume. 1,4-Dithiothreitol (DTT), 
loading buffer (LB).  
Cell line 20 µg loading (µL) Water (µL) DTT 10x (µL) LB 4x (µL) Σ (µL) 
GLIOMA 2.7 3.8 1 2.5 10 
MCF-7 0.9 5.6 1 2.5 10 
T-47D 1.0 5.5 1 2.5 10 
SK-BR-3 0.9 5.6 1 2.5 10 
MDA-MB-231 1.7 4.8 1 2.5 10 
MDA-MB-361 1.4 5.1 1 2.5 10 
MCF-10A 4.9 1.6 1 2.5 10 
 
3.3.3 Western blot wet transfer  
After electrophoretic protein separation, the proteins were transferred onto the PVDF membrane, 
to achieve accessibility for antibody binding and recognition. PVDF membrane was activated by 
soaking in methanol for 1 min, washed in water for the same amount of time, and left to incubate 
in WB transfer buffer for 20 min. Filter paper and sponges were soaked in transfer buffer before 
usage. Once the membrane was activated, we removed the gel from the plates, and were able to 
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start constructing the transfer “sandwich”, as shown in Figure 4. The assembled sandwich was 
inserted in the blotting electrode inside the buffer tank, which was filled with the transfer buffer 
and an additional cooling unit was added. The transfer was left for 90 min at 90 V. The laboratory 
equipment and chemicals used for wet transfer are shown in Table 24 and Table 25. 
Table 24. Laboratory equipment for western blot wet transfer  
Laboratory equipment Manufacturer 
Blotting electrode 
BioRad, #1658035 
Blotting cassette  
Sponge 
Buffer tank 
Lid with power cables 
PowerPac HC power supply 
Cooling unit 
Filter paper  / 
PVDF membrane Millipore,  #IPVH00010 
 
Table 25. Chemicals for western blot wet transfer  
Chemicals Manufacturer 
Methanol Sigma, # 322415 
WB transfer buffer  See Table 26 
 
Table 26. WB transfer buffer (1x) 
Chemicals Volume Manufacturer 
Trizma base 3.03 g Sigma, #T6066 
Glycine 14.41 g Sigma, # G8898 
Methanol 0.2 L Sigma, # 322415 
dH2O Fill to final 1L / 
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Figure 4. Schematic representation of the wet transfer “sandwich”. 
3.3.4 Protein detection  
After successful transfer of proteins from the gel to the PVDF membrane, it was incubated in 5 % 
solution of non-fat dry milk (diluted with PBST (1x)) for 1 h at room temperature (RT) to prevent 
unspecific antibody binding. After blocking, the membrane was left to incubate on a shaker at 4 
°C overnight in selected concentration of primary antibody solution, diluted in 1 % solution of 
non-fat dry milk (Diluted with PBST (1x)). Table 31 shows the list of primary antibodies used for 
protein detection. The following day, the membrane was left at RT and washed 3x in PBST for 10 
min. Once the membrane was washed from unbound primary antibodies, a selected concentration 
of secondary antibodies diluted in 1 % milk was added, and left to incubate with shaking at RT for 
1 h. The list of secondary antibodies used for protein detection is presented in Table 32. All of the 
used secondary antibodies had a conjugated Horseradish peroxidase enzyme (HRP), which 
allowed us to visualize binding to primary antibodies, after addition of appropriate substrate. After 
incubation in secondary antibodies, the membrane was once more washed in PBST (1x), following 
the previous protocol. After the final PBST wash, the membrane was washed in PBS to remove 
excess detergent, and left in PBS until it underwent protein detection. For detection, we used 
SuperSignal West Pico PLUS, chemiluminescent substrate, mixed in a 1:1 ratio of luminol and 
peroxide. After the final incubation, the membrane was removed from PBS, put in plastic 
membranes and 1 mL of chemiluminescent substrate was added on to the membrane. The 
membrane was left to incubate 3-4 min for the substrate to work. Chemiluminescent light from the 
LAS 4000 camera was used to detect proteins, and Multi Gauge computer program for image 
processing. To test that the loading amount was consistent across the lanes of our gel, we needed 
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to normalize detected CBs against a normalization control. For our normalization control, we used 
the constitutively expressed housekeeping protein glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH). Our membranes, which were post-imaging stored at -20 °C in PBS were defrosted and 
incubated in 5 % solution of non-fat dry milk for 1 h at RT. After blocking in 5 % milk, our 
membranes were left overnight to incubate in Anti-GAPDH antibody diluted in 1 % non-fat dry 
milk. Secondary antibody incubation, membrane washing and protein detection was done 
following the same protocol as described above. Table 27 and Table 28 show the laboratory 
equipment and chemicals used for protein detection.  
Table 27. Laboratory equipment for protein detection 
Laboratory equipment Manufacturer 
Compact Digital Waving Rotator Thermo Fisher, #88880022  
LAS 4000  
Fujifilm 
Multi Gauge computer program 
 
Table 28. Chemicals for protein detection  
Chemicals Manufacturer 
Non-fat dry milk Prekomurske mlekare 
PBS (1x) See Table 29 
PBST (1x) See Table 30 
SuperSignal West Pico PLUS Thermo Fisher, #34580 
 
Table 29. PBS (10x). For mixing PBS (1x), dilute adequate volume of (10x) in dH2O 
Chemicals Volume Manufacturer 
Na2HPO4x12H2O 32.23 g Fluka BioChemika, #71649 
KH2PO4 1.36 g Sigma, #04243 
NaCl 87.8 g Sigma, #S7653 
dH2O Fill to final 1L / 
 
Table 30. PBST (10x) 
Chemicals Volume Manufacturer 
PBS (1x) 500 mL See Table 30 
Tween 20 500 µL Sigma, #P7949 
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Table 31. Primary antibodies used in the WB protein detection experiment 
Antibody Type Source Concentration Dilution Manufacturer 
Anti-Cannabinoid 
Receptor I 
antibody 
Polyclonal Rabbit 1 mg/ml 1:500 
Abcam, 
#ab23703 
Anti-Cannabinoid 
Receptor II 
antibody 
Polyclonal Rabbit 1 mg/ml 1:500 
Abcam, 
#ab45942 
CB1 Antibody Monoclonal Mouse 1 mg/ml 1:500 
Santa Cruz 
Biotechnology, 
#sc-518035 
CB2 Antibody Monoclonal Mouse 1 mg/ml 1:500 
Santa Cruz 
Biotechnology, 
#sc-293188 
Anti-GAPDH Polyclonal Mouse 1 mg/ml 1:5000 Sigma, #G8795 
 
Table 32. Secondary antibodies used in the WB protein detection experiment 
Antibody Type Source Concentration Dilution Manufacturer 
HRP Goat Anti-
Rabbit (IgG) 
secondary 
antibody 
Polyclonal Goat 2 mg/ml 1:4000 Abcam, #ab205718 
Goat Anti-Mouse 
(IgG) Secondary 
Antibody 
Polyclonal Goat 1 mg/ml 1:5000 
Jackson Immuno 
Research, #115-
035-068 
 
3.3.5 Normalization and quantification 
To quantify our proteins against normalization GAPDH, and to determine the exact molecular 
weight of our signal, we used the computer program Image J (Table 33). Quantification 
measurements are based on signal intensity, with histograms showing each protein band. The 
higher the histogram, the higher the intensity and the brighter the band. Intensity values are shown 
as numerical area values, which corresponds to the surface under each histogram. The background 
signal was removed by hand for each histogram, leaving intensity values corresponding only to 
our protein signal. 
Table 33. Laboratory equipment for normalization and quantification 
Laboratory equipment Manufacturer 
Image J computer program National Institutes of Health  
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3.4 Immunocytochemistry 
The immunocytochemistry (ICC) method was used to characterize the expression and localization 
of CBs in whole breast cancer cell lines. The technique is based on specific primary antibody 
binding to the desired target. Upon primary binding, a secondary antibody was used, which bound 
to our primary antibody. The secondary antibody acted as a chromophore, as it enabled 
visualization of primary antibody binding. This allowed us to determine the expression and 
localization of our desired protein in cell lines. We used previously prepared slides (See section 
3.1.4) with fixed breast cancer cell lines. Each ICC analysis was done in duplicates.  
3.4.1 Blocking of nonspecific antibody binding   
Slides with fixed cell lines were incubated in the blocking buffer. This step is important as it 
prevents unspecific primary protein binding, resulting in false validation. Slides were taken out of 
storage (-20 °C), and were left a few min to dry. On top of the slides, we put eight well stickers, 
which allowed us to have more than one reaction on the slides. Each well was filled with 50 µl of 
blocking buffer (Table 34), and left for 1 h at RT for the reaction to take place. It was important to 
make certain that there were no air bubbles, as they would interfere with successful blocking.  
Table 34. ICC Blocking buffer  
Chemicals Volume Manufacturer 
FBS 500 µL Gibco, #10500-064 
BSA 0,05 g Sigma, #A9418-500G 
DPBS (10x) 500 µL Gibco, #14200-067 
dH2O Fill to 5 mL / 
 
3.4.2 Primary antibody incubation  
After slide blocking, to prevent false validation, we added primary antibody solutions, which were 
diluted in antibody dilution buffer. We tested one of the commercially most used polyclonal 
antibodies manufactured by Abcam against CB1 and CB2, and where amongst the first to test the 
new monoclonal antibody manufactured by Santa Cruz Biotechnology against both CBs  
(Table 36). Abcam antibodies have additional available synthetic blocking peptides (BP), which 
can be added simultaneously with compatible antibodies to ensure additional validation of binding 
specificity. Synthetic peptides have identical epitopes as proteins, which specific antibodies 
recognize and bind to. The addition of BP would lower the staining intensity, as the antibodies 
would preferentially bind to easily accessible peptides available in the solution, rather than to 
protein epitopes. Blocking buffer was removed from each well, except from the control. All 
antibodies and BP were diluted in antibody dilution buffer (Table 35) Then, the diluted primary 
antibody was added to each well (50 µL). It was important to make certain that there were no air 
bubbles. The general slide scheme which we held on during the ICC experiment is shown in Figure 
5. Slides with the diluted primary antibodies were left to incubate overnight at 4°C. 
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Table 35. ICC Antibody dilution buffer  
Chemicals Volume Manufacturer 
BSA 5,0 g Sigma, #A9418-500G 
DPBS (10x) 50 mL Gibco, #14200-067 
dH2O 450 mL - 
 
Table 36. Primary antibodies and blocking peptide used in the ICC experiment. Multiple dilutions were tested 
in some examples 
Antibody Type Source Concentration Dilution Manufacturer 
Anti-
Cannabinoid 
Receptor I 
antibody 
Polyclonal Rabbit 1 mg/ml 
1:200 
1:100 
Abcam, 
#ab23703 
Anti-
Cannabinoid 
Receptor II 
antibody 
Polyclonal Rabbit 1 mg/ml 
1:500 
1:200 
Abcam, 
#ab45942 
Cannabinoid 
Receptor I 
peptide 
- - 1 mg/ml 1:80 
Abcam, 
#ab50542 
Cannabinoid 
Receptor II 
peptide 
- - 1 mg/ml 1:50 
Abcam, 
#ab45941 
CB1 Antibody Monoclonal Mouse 1 mg/ml 1:50 
Santa Cruz 
Biotechnology, 
#sc-518035 
CB2 Antibody Monoclonal Mouse 1 mg/ml 
1:50 
1:200 
Santa Cruz 
Biotechnology, 
#sc-293188 
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Figure 5. Graphical representation of an ICC working slide. Primary antibodies and their respective BP where 
added to each well in the order shown on the slide sheme. 1. CB1 Abcam, 2. CB1+BP Abcam, 3. CB2 Abcam, 4. 
CB2+BP Abcam, 5. CB1 Santa Cruz, 6. CB2 Santa Cruz, 7. Control (blocking buffer), 8.- 
3.4.3 Secondary antibody incubation  
After overnight incubation, primary antibodies were removed from the wells. Each one was 
washed three times in PBS (1x) before secondary antibodies conjugated with HRP were added 
(Table 37). The primary and secondary antibodies were diluted with the same dilution buffer. 
Secondary antibodies were added to each well (50 µL), depending on their primary source (rabbit 
or mouse), and were left to incubate for 1 h at RT.  
Table 37. Secondary antibodies used in the ICC experiment 
Antibody Type Source Concentration Dilution Manufacturer 
Anti-Rabbit IgG 
(H+L), HRP 
Conjugate 
Polyclonal Goat 2 mg/ml 1:200 
Promega, 
#W401B 
Anti-Mouse IgG 
(H+L), HRP 
Conjugate 
Polyclonal Goat 1 mg/ml 1:200 
Promega, 
#W402B 
 
3.4.4 ICC Staining  
After secondary antibody incubation was completed, the antibody solution was removed from each 
well, which were again washed three times in PBS (1x). DAB substrate kit was used for 
peroxidase-based staining detection. The 50 µL of mixed DAB solution (1.5 mL of DAB substrate 
with 30 µL of DAB chromogen) was added to each well, and was left to incubate for 10 min at 
RT. Following the incubation, the slides were washed two times for 5 min in dH2O at RT. After 
washing, excess water was removed, and the slides were ready for nuclear staining with Harris's 
hematoxylin from the Peroxidase IHC detection kit. Hematoxylin was diluted with PBS (1x) in a 
1:1 ratio. Approximately 500 µL of hematoxylin solution was added to each slide, and was left to 
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incubate for 45 s at RT. The solution was washed from the slides with tap water, and was 
additionally washed in dH2O for a few min. The chemicals used for slide staining are shown in 
Table 38. 
Table 38. Chemicals for slide staining   
Chemicals Manufacturer 
DAB substrate kit Abcam, #ab64238 
Hematoxylin Thermo Scientific, #36000 
 
3.4.5 Dehydration  
The stained slides were dehydrated by submersion in an increasing ethanol gradient of 70 %,  
96 %, and absolute, for 3 min in each solution. Next, the slides were submerged two times in 
xylene for 2 min. The chemicals used for dehydration are shown in Table 39. 
 
Table 39. Chemicals for dehydration   
Chemicals Manufacturer 
Ethanol Merck, #1.00983.2500 
Xylene Chem-Lab NV, #CL00.2402.1000 
 
3.4.6 Slide preparation and microscopy  
Following the submersion in xylene, the slides were left to dry. On dry slides, we added 2-3 drops 
of antifade reagent, which was spread evenly across the slide. Microscopy cover slips were 
carefully placed over the reagent drops. It was important to avoid air bubbles, as they interfere 
with successful microscopy. We used an inverted microscope to observe cell morphology and ICC 
slides. The microscope was connected to a camera, which allowed us to take cellular pictures at a 
10x and 20x magnification. The captured images were processed using image analysis software. 
The laboratory equipment and chemicals used for slide preparation and microscopy are shown in 
Table 40 and Table 41. 
Table 40. Chemicals used for slide preparation   
Chemicals Manufacturer 
ProLong Gold Antifade Mountant Invitrogen, #P36930 
 
Table 41. Laboratory equipment used for slide microscopy   
Laboratory equipment Manufacturer 
Inverted microscope Eclipse Ti Nikon 
Camera DS-U2/L2 Nikon 
Program NIS-Elements AR 4.13 Nikon 
  
Fran Krstanović. Določitev kanabidoidnih receptorjev v celičnih linijah raka dojke. Magistrska naloga. Univ. 
v Ljubljani, FKKT, 2019.  
33 
 
3.5 Cell viability test  
From a pool of breast cancer cell lines, three cell lines were selected for cell viability assay (MTT 
assay) with the aim to cover all breast cancer phenotypes (Table 42). Based on our preliminary 
ICC results, we chose T-47D over MCF-7 as hormone positive (they possess the same phenotype), 
SK-BR-3 was selected as HER2+ and MDA-MB-231 as triple-negative. Each cell line was 
cultured in a 96-well plate and, based on their phenotype, was treated with a range of 
concentrations of CBD and a suitable therapeutic approach. TAM was selected for hormone 
positive, CIS for triple negative and HER for HER2+. Post-treatment colorimetric MTT assay was 
used for testing cytotoxic effects of individual compounds on breast cancer cells. The method is 
based on the ability of metabolic active cells to reduce yellow compound MTT ((1-(4,5 
dimethyltiazol-2-yl)-2,5 diphenyl tetrazolium bromide) into insoluble purple formazan crystals 
with the enzyme succinate dehydrogenase in the mitochondrion. The crystals were dissolved in 
DMSO. The ratio of the amount of formed formazan to the number of living cells is linear and 
specific for each cell line. Viability was tested in a minimum of three biological repeats, within 
each, three technical repeats.  
Table 42. Cell lines, their phenotypes and compounds used in MTT cell viability tests. Cannabidiol (CBD).  
Cell line Phenotype Cannabinoid Therapeutic  
T-47D  ER+, PR+, HER2 - 
CBD 
4-OH tamoxifen 
SK-BR-3 ER-, PR-, HER2 + cisplatin 
MDA-MB-231 ER-, PR-, HER2 - Herceptin 
 
3.5.1 96-well plate cell culturing  
Cell lines were grafted with the same protocol as in Section 3.1.3. Each well was filled with 200 
µL of cells solution in their appropriate medium. Cells within the solution were counted using a 
hemocytometer counting-chamber and were diluted accordingly, so that the final cell count per 
well was 6000 cells/200 µL. For cell counting, the solution was diluted in a 1:1 (50 µL:50 µL) 
ratio with trypan blue dye. The 50 µL of the mixture was put in the counting chamber. Cell count 
per mL was obtained using the following formula:  
𝑁 =
𝛴𝐶𝑒𝑙𝑙𝑠 𝑖𝑛 𝑒𝑎𝑐ℎ 𝑞𝑢𝑎𝑑𝑟𝑎𝑛𝑡
𝑛
 𝑥 𝑅 𝑥 𝐾𝑝 
N-Number of cells, n-Number of counted quadrants, R-Dilution factor, Kp-Hemocytometer factor 
All work was done under sterile conditions in the cell laminar. Plates were stored overnight in a 
CO2 cell incubator at 37 °C to achieve adhesion. Table 43 and Table 44 present the laboratory 
equipment and chemicals used for 96-well plate cell culturing. 
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Table 43. Laboratory equipment for 96-well plate cell culturing    
Laboratory equipment Manufacturer 
96-well plate  Thermo Scientific, #167008 
Hemocytometer Sigma, #BR717805 
 
Table 44. Chemicals for 96-well plate cell culturing    
Chemicals Manufacturer 
Trypan blue dye Sigma, #T8154 
 
3.5.2 Preliminary cell treatment  
Overnight adhesion of cells was confirmed using an optical microscope. Cells were cultured up to 
a 60-70 % confluency. Apart from HER, we diluted each compound in their appropriate solvent in 
a Stock solution concentration of 1 mg/ml (Table 45). Herceptin was acquired diluted in a saline 
solution from the Oncology Institute in Ljubljana. These diluted compounds were further diluted 
in an appropriate cell medium, to achieve desired compound concentrations in a 200 µL/well. 
Preliminary treatment scheme is shown in Figure 6. All work was done under sterile conditions in 
the cell hood. Compounds were added to the cells and cell plates were stored for 48 h or 72 h 
(depending on the cell line) in a CO2 cell incubator at 37 °C. Table 45 lists compound properties 
used in cell treatment.  
Table 45. Property of compounds used in cell treatment  
Compound Solvent 
Mr 
(g/mol) 
c (M) for 1 
mg/ml 
Manufacturer 
CBD  70 % EtOH 314.5 50 mM Tocris, #1570 
4-OH tamoxifen Methanol 387.5 12,9 mM Sigma, # H7904 
cisplatin DMSO 300.1 3.3 mM Sigma, # 479306 
Herceptin Saline solution 145.6x103 144 µM N3017H02-OIL 
 
3.5.3 MTT Assay  
After the cells achieved sufficient growth, and were incubated with CBD or their respective 
therapeutic for a determined period of time, the medium solution was removed from each well. 
MTT (20 µl) was added to each well, and plates were left to incubate for 3 h in a CO2 cell incubator 
at 37 °C. Post incubation, 20 µL of DMSO was added to each well. Well absorbance was measured 
at 570/690 nm using a spectrophotometer. The percentage of cell viability was normalized to the 
control cells without treatment (cells grown in medium). Data were analyzed using Prism 6 
software. The laboratory equipment and chemicals for MTT assay are shown in Table 46 and Table 
47. 
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Table 46. Laboratory equipment for MTT assay    
Laboratory equipment Manufacturer 
Spectrophotometer   NanoDrop 1000, Spectrophotometer, TFS 
Prism 6 software GraphPad 
 
Table 47. Chemicals for MTT assay    
Chemicals Manufacturer 
 MTT  Sigma, #M5655-1G 
DMSO Sigma, #D8418 
 
3.5.4 Combinational treatment in MTT assay  
Based on preliminary IC80 values, we selected appropriate concentrations of CBD and therapeutic 
to test for combinational effects (Table 48.). Once the cells achieved adhesion and satisfactory 
confluency, they were subjected to their respective treatment. CBD and matching therapeutics 
were added separately to each well and left to incubate for a determined period of time, depending 
on the cell line.  
 
Table 48. Phenotype specific combinational treatment. Cannabidiol (CBD), 4-OH tamoxifen (TAM), cisplatin 
(CIS), Herceptin (HER). 
Cell line Phenotype Combinational treatment 
T-47D  ER+, PR+, HER2 - CBD+TAM 
SK-BR-3 ER-, PR-, HER2 + CBD+HER 
MDA-MB-231 ER-, PR-, HER2 - CBD+CIS 
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Figure 6. Schematic representation of the preliminary cell viability experiments on selected breast cancer cell 
lines. Treatment of a) ER+/PR+ T-47D cell line. b) HER2+ SK-BR-3 cell line. c) Triple-negative MDA-MB-231 cell 
line. Cannabidiol (CBD), 4-OH tamoxifen (TAM), cisplatin (CIS), Herceptin (HER). 
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4 RESULTS AND DISCUSION 
4.1 Pre-experimental analysis and successful cell culturing  
4.1.1 CBs mRNA expression data from CCLE proteomic database 
We used CCLE database to obtain information on mRNA expression levels of cannabinoid 
receptors CB1 and CB2 in the selected breast cancer cell lines. All data deposited in CCLE were 
obtained using new generation sequencing (RNA-Seq). Transcript levels are very low in all 
analyzed cell lines (Figure 7b). This does not necessary mean that their protein levels are equally 
low as mRNA transcript levels do not necessarily correlate to protein levels. Detected values can 
vary due to transcription/expression level and stability (low abundant proteins often show a high 
transcription rate), mRNA regulatory processes and cell perturbation (cancer state) [38]. 
a) 
 
b) 
Cannabinoid 
receptor 
Breast cancer cell line (TPM) 
MCF-7 MDA-MB-231 MDA-MB-361 SK-BR-3 T-47D 
CB1 0 0.1 9 0 0 
CB2 0.1 0.1 0.1 0.1 0.2 
 
Figure 7. Expression levels of CBs based on CCLE data. a) Heatmap. The increase in expression values is 
proportional to the darkness of the blue color. Grey represents no available data. b) Expression values. CBs mRNA 
expression level values in transcripts per million (TPM). Expression levels: below cutoff (<0.5 TPM), low (0.5-10 
TPM), medium (11-1000 TPM), high (+1000 TPM). 
4.1.2 CBs protein and mRNA expression data from the literature  
Apart from CCLE database information, additional validation information was obtained from 
extensive study of peer research articles on the selected breast cancer cell lines and CBs. Diverse 
methods were used in hopes of detecting CBs, and various antibodies. The results are summarized 
in Table 49. 
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Table 49. CBs expression data from the literature. SK-BR-3 CB1 expression is denoted as +/- due to inabilty to 
confirm with certainty receptor presence. The author lack to comment on the very low intensity, bearly visible WB 
signal [31].  
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4.1.3 Successful adhesion and growth of selected breast cancer cell lines 
We successfully cultured all of the selected breast cancer cell lines. Apart from T-47D cell line, 
all the lines showed sufficient growth rate and adhesion, in line with the ATTC database medium 
recommendations (Table 3). However, the first T-47D cell batch lacked adhesion in RPMI-1640 
medium (with added insulin, BSA and P/S), as recommended by the ATTC database. The second 
batch of cells was dived into two; the first was cultured in RPMI-1640 medium, while the second 
in DMEM medium. Once again, T-47D showed lack of adhesion in RPMI-1640 medium, but 
achieved successful adhesion and growth in DMEM medium. Subsequently, T-47D cell line was 
efficiently cultured in DMEM medium. Like in the majority of cancer cells, we observed 
morphological and behavioral cancer cell hallmarks in selected breast cancer cell lines [39]. Some 
of the observed morphology changes are: spherical single cell shapes, small cytoplasm, 
large/multiple nuclei (higher mitosis rate), and colony formation (high cell density). Behavioral 
traits are: loss of contact inhibition, fast and spontaneous proliferation (without added growth 
factors) and infinite division (immortalization) [39]. The morphology of selected breast cancer cell 
lines is shown in Figure 8. All observed cell morphologies correlate with their respective 
morphology pictures in the ATCC database.  
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Figure 8. Cell morphology of selected breast cancer cell lines. Pictures were obtained with 20x magnification under 
an inverted microscope. Scale bar represents 50 µm. 
4.2 Determining protein concentration using BCA assay 
We used RIPA extraction buffer to isolate proteins from cell pellets of selected breast cancer cell 
lines. To determine the protein concentration in lysates, we used the BCA assay. Calibration curve 
was based on measured ascending BSA standard absorbance. Measured BSA absorbance duplicate 
show similar values (Table 50). The final sample concentration (mg/mL) was obtained by plotting 
measured absorbance values on the calibration curve (Figure 9). 
Table 50. Protein standard measurements  
Standard 
(mg/mL) 
0 1.25 2.5 5 7.5 10 15 20 
Series 1 0.135 0.225 0.289 0.498 0.659 0.773 1.063 1.434 
Series 2 0.127 0.192 0.266 0.413 0.579 0.63 0.941 1.466 
 
 
Figure 9. Calibration curves for determining protein concentrations. a) Series 1 b) Series 2   
The first series of cell lysates were measured in 10x dilution with RIPA buffer. Due to a low 
number of available pellets, cell lines MDA-MB-361 and MCF-10A were left out of the first 
isolation series, until an optimal isolation method was established.  
Table 51. Protein concentration in lysed breast cancer cells (Series 1) 
Cell line GLIOMA MCF-7 T-47D SK-BR-3 
MDA-MB-
231 
MDA-
MB-361 
MCF-
10A 
Dilution  10x 10x 10x 10x 10x - - 
Absorbance 
0.559 1.344 1.226 0.713 0.802 - - 
0.563 1.4 1.273 0.734 0.836 - - 
Average 0.561 1.372 1.249 0.724 0.819 - - 
10x diluted 
concentration 
(mg/mL)  
0.7 1.92 1.73 0.9 1.06 - - 
Concentration 
(mg/mL)  
7 19.2 17.3 9.1 10.6 - - 
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In the second isolation series, we sonicated cell lysates prior to centrifugation to obtain higher 
protein yields. The second series of cell lysates were measured in 10x and 50x dilution with RIPA 
buffer. 
Table 52. Protein concentration in lysed breast cancer cells (Series 2)   
Cell line GLIOMA MCF-7 T-47D SK-BR-3 
MDA-MB-
231 
MDA-MB-
361 
MCF-10A 
Dilution  10x 50x 10x 50x 10x 50x 10x 50x 10x 50x 10x 50x 10x 50x 
Absorbance 
(A) 
0.56 0.28 1.58 0.89 1.32 0.68 1.54 0.64 0.79 0.41 0.98 0.43 0.35 0.19 
0.57 0.27 1.57 1.06 1.43 0.69 1.59 0.65 0.89 0.44 1.03 0.46 0.34 0.23 
Average 0.56 0.27 1.57 0.98 1.38 0.69 1.57 0.65 0.85 0.43 1.00 0.45 0.35 0.22 
Diluted 
concentration 
(mg/mL) 
0.8 0.3 2.3 1.4 2.0 0.9 2.3 0.9 1.2 0.5 1.4 0.6 0.4 0.2 
Concentration  
(mg/mL) 
7.5 23.2 20.1 23.1 11.8 14.3 4.1 
 
The final concentrations were determined from the 10x dilution. The measured concentration 
values varied between cell lines, with the lowest yield in MCF-10A (4.1 mg/mL) and the highest 
in MCF-7 (23.2 mg/mL). All the measured values were in an optimal concentration range, and 
were sufficient for applying 20 µg of protein in a 10 µL finale volume. Undiluted samples were 
further used for WB. The loading mixture for each cell line is shown in Table 24.  
4.3 Selected breast cancer cell lines express CBs on a protein level 
To unify the quantity of proteins in the samples, we calculated the amount of loading volume for 
PAGE based on measured concentrations, in a way that 20 µg of protein are applied in a 10 µL 
final volume (Table 24). We used the WB method to test the specificity of antibodies and to 
determine the level of expression of CB1 and CB2 in selected breast cancer cell lines. Glioma cells 
isolated from patient cancerous tissue were used as a positive control for both CB1 and CB2. 
Optimal primary and secondary antibody concentrations were chosen based on Dot-blot results 
from the Diploma thesis by Patrik Levačić. GAPDH was chosen as normalization protein, as it 
showed the most optimal results for normalization in the selected breast cancer cell lines, based on 
results from the Master’s thesis by Mateja Cigoj [40]. Other well established housekeeping 
proteins in WB normalization such as β-actin, vinculin and cyclophilin A lacked a uniform pattern 
of expression in selected breast cancer cell lines [40]. Molecular weight and protein quantification 
against our normalization protein was measured using ImageJ software. 
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4.3.1 Detection of CBs expression using Abcam antibodies  
CB1 and CB2 detection using polyclonal antibodies was done on separate membranes. In CB1 
detection, we expected signals in the interval of 53-60 kDa, but were observed at 111-113 kDa 
interval in both control and breast cancer cells (Figure 10a). However, no specific signal was 
observed in the predicted interval, which could either confirm the presence of CB1 at higher 
signals, or that the polyclonal CB1 antibody binds unspecific, and therefore is unable to detect CBs 
in the tested breast cancer cell lines. Unfortunately, as far as we know, there is no available 
literature data on Abcam CB1 antibody in breast cancer cell lines, which would help validate the 
results, although receptor expression and literature data suggest positive expression of CB1 in the 
majority of tested cell lines. The high intensity signal around 40 kDa should be disregarded, as it 
was only observed in the T-47D and does not correspond to appropriate CB1 receptor signal. The 
presence of CB1 at higher signals could be explained by the formation of receptor multimers, in 
our case dimerization, as the signal size corresponds to double the expected molecular weight. 
Further tests with addition of the BP, and increasing reducing conditions would need to confirm 
the accuracy of this prediction. Interestingly, Abcam antibodies were able to detect CB1 at a 
predicted signal in other cell types, such as synovial or neural [45–48]. Normalization protein 
GAPDH showed adequate band size at 37 kDa and uniform expression levels across all cell lines 
(Figure 10a and 10b). 
Using Abcam Anti-CB2 antibodies for WB immunodetection showed much more promising 
results for CB2 detection in the breast cancer cell lines. We observed CB2 specific signals at 36-
42 kDa, which deviated slightly from the 45 kDa manufacturer predicted band size (Figure 10b). 
This slight deviation could be due to the membrane incidence, which is shown to affect image 
processing as the obtained molecular weight decreases proportionally from the left side to the right 
(Figure 10c). Despite slight size deviation, corresponding signals should be regarded as CB2 
protein. Similar to the Abcam CB1 antibody, higher signals corresponding to receptor dimerization 
were observed. Interestingly, except in T-47D cell line, all other tested cells show to express CB2, 
which correlates with receptor expression data and available literature data using other CBs 
antibodies. Using an identical antibody, Elbaz, et al., showed that CB2 is highly expressed in  
MCF-7, MDA-MB-231 and T-47D cell lines [45]. Unfortunately, we were unable to obtain the 
same result for our T-47D cell line. This deviation could be due to loss of receptor expression in 
our cell line or unsuccessful protein transfer. Signal intensity deviated, as control glioma,  
MDA-MB-231 and MCF-10A showed higher intensity in comparison to MCF-7 and SK-BR-3. 
Normalization protein GAPDH showed adequate band size at 37 kDa and uniform expression 
levels across all cell lines (Figure 10b). 
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Figure 10. Detection of CBs in selected breast cancer cell lines with Abcam polyclonal antibodies. a) WB analysis 
with Abcam Anti-CB1 antibody. b) WB analysis with Abcam Anti-CB2 antibody. Protein loading volume was 20 µg. 
Glioma cell line represents positive control. c) Measured molecular weight of Abcam CB1 and CB2 signals using 
Image J processing program. d) Protein quantification using ImageJ software for CB1 e) Protein quantification using 
ImageJ software for CB2. 
Comparative quantitative results with polyclonal Abcam antibodies 
The levels of CB1 receptors vary among the cells (as normalized to GADPH protein) as follows: 
T-47D >MDA-MB-231>MCF-7>SK-BR-3>MCF-10A>MDA-MB-361 
The levels of CB2 receptors vary among the cells (as normalized to GADPH protein) as follows: 
MCF-10A >MDA-MB-231>MDA-MB-361> MCF-7<SK-BR-3>MCF-10A>T-47D 
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4.3.2 Detection of CBs expression using Santa Cruz antibodies 
CBs detection using monoclonal antibodies from Santa Cruz showed promising results. Measured 
CB1 signals showed a 50-54 kDa interval in molecular weight, which corresponds to the 
manufacturer’s predicted 50-55 kDa band size (Figure 11a). Santa Cruz CB1 antibody showed 
highly specific immunodetection, as no signals apart from the 50-54 kDa CB1 were detected. 
Interestingly, unlike in the case of CB1 polyclonal antibody, Santa Cruz monoclonal did not detect 
receptor multimers. This could be due to the inaccessible binding epitope in the multimer form. 
WB results showed that CB1 is expressed in all selected breast cancer cell lines, but with different 
intensities. Hirao-Suzuki, et al., obtained the same band size for CB1 in MDA-MB-231 cell line 
[46], whereas  
MCF-7, T-47D and SK-BR-3 cell lines expression was higher than in other cell lines and deviated 
from CCLE expression values. Normalization protein GAPDH showed adequate band size at 
37kDa satisfactory expression levels across all cell lines.  
High intensity CB2 signals were measured in the 63-68 kDa interval, which correlates with Santa 
Cruz predicted size (Figure 11b). Amongst all tested CBs antibodies, CB2 Santa Cruz showed the 
highest background staining. The receptor was shown to be expressed in all tested cell lines, with 
high intensity, apart from the control glioma cell. This can be interpreted that CB2 is more 
expressed in peripheral tissue than in the brain. MDA-MB-231 band size corresponds to Hairao-
Suzuki, et al. results, while positive expression of CB2 across all tested cell lines correlates with 
literature data and mRNA expression values [46]. Normalization protein GAPDH showed 
adequate band size at 37 kDa and uniform expression levels across all cell lines.  
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Figure 11. Detection of CBs in selected breast cancer cell lines with Santa Cruz monoclonal antibodies. a) WB 
analysis with Santa Cruz CB1 antibody. b) WB analysis with Santa Cruz CB2 antibody. Protein loading volume was 
20 µg. Glioma cell line represents positive control. c) Measured molecular weight of Santa Cruz CB1 and CB2 signals 
using Image J processing program. d) Protein quantification using ImageJ software for CB1 e) Protein quantification 
using ImageJ software for CB2. 
Comparative quantitative results with monoclonal Santa Cruz antibodies 
The levels of CB1 receptors vary among the cells (as normalized to GADPH protein) as follows:  
SK-BR-3>T-47D> MCF-7>MDA-MB-231> MCF-10A>MDA-MB-361 
The levels of CB2 receptors vary among the cells (as normalized to GADPH protein) as follows: 
T-47D> MCF-10A>MDA-MB-231>MCF-7>SK-BR-3> MDA-MB-361 
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4.3.3 CBs antibody comparison  
All tested antibodies were able to detect CBs in glioma control cells with moderate or low intensity 
signals (Figure 12.). As tested antibodies differ in clonality (polyclonal Abcam, monoclonal Santa 
Cruz), factors such as epitope type, localization and accessibility can cause result discrepancy. 
In MCF-7 both sets of antibodies were able to detect CBs. Abcam antibody detected CB1 with 
higher intensity, in comparison to Santa Cruz, while the opposite was observed for CB2; Santa 
Cruz CB2 detection showed much higher intensity than Abcam CB2.   
However, the most inconsistent results were observed in T-47D cell line, as Abcam CB2 was 
unable to detect CB2, while Santa Cruz antibody showed a fairly intensive band. On the other 
hand, Abcam CB1 showed much higher intensity in comparison to Santa Cruz. 
Santa Cruz antibodies detected both CBs with higher intensity in comparison to Abcam antibodies 
in SK-BR-3 cell lines. Both CB1 antibodies showed positive detection, which differs from 
available literature data for CB1 expression in SK-BR-3 cell line.  
In MDA-MB-231 cell line Abcam antibody detected CB1 with high intensity in comparison to low 
intensity band with Santa Cruz antibodies. CB2 was detected at a similar signal intensity.  
In MDA-MB-361 and MCF-10A cell lines, both tested sets of antibodies showed similar results; 
very low signal intensity in CB1 detection, while high intensity in CB2 detection. As to the best 
of our knowledge there is no available literature data on CBs expression in MDA-MB-361 cell 
line, this is the first time that specific signals with both sets of antibodies have been achieved in 
MDA-MB-361 cells. 
 
Figure 12. Comparison of antibody specificity in detecting CBs with polyclonal (Abcam) and monoclonal (Santa 
Cruz) CB1 and CB2 antibodies. a) Comparison in detecting CB1 using Abcam or Santa Cruz antibodies. b) 
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Comparison in detecting CB2 using Abcam or Santa Cruz antibodies. Protein loading volume was 20 µg. Glioma cell 
line represents positive control.  
Quantitative comparison of polyclonal (Abcam) with monoclonal (Santa Cruz) antibodies 
The levels of CB1 receptors vary among the cells (normalized to GADPH protein) as follows:  
Polyclonal Abs: T-47D >MDA-MB-231>MCF-7>SK-BR-3>MCF-10A>MDA-MB-361 
Monoclonal Abs: SK-BR-3>T-47D> MCF-7>MDA-MB-231> MCF-10A>MDA-MB-361 
The levels of CB2 receptors vary among the cells, (normalized to GADPH protein) as follows: 
Polyclonal Abs: MCF-10A>MDA-MB-231>MDA-MB-361>MCF-7>SK-BR-3 >T-47D 
Monoclonal Abs. T-47D> MCF-10A>MDA-MB-231>MCF-7>SK-BR-3> MDA-MB-361 
 4.4 CBs cellular staining varies among selected breast cancer cell lines 
After confirming the expression of CBs in breast cancer cell lines on a protein level, we determined 
the receptor expression on a cellular level with ICC. An identical set of antibodies, as previously 
used for WB experiments, was used for ICC staining. To our knowledge, we were the first to apply 
both sets of antibodies for CBs on the selected breast cancer cell lines. All staining experiments 
were done in duplicates to ensure result reproducibility. Since there is no available reference data, 
we used our WB values, CCLE receptor expression data and literature data to validate ICC 
staining. Abcam BP with its compatible antibody served as an additional point of validation. 
Unfortunately, it was not possible to additionally validate Santa Cruz antibodies in the form of BP 
because the manufacturer did not provide any. 
4.4.1 CB1 immunolabeling  
We used a commercially popular, polyclonal antibody manufactured by Abcam for detection of 
CB1 in the selected breast cancer lines. Additionally, Abcam synthetic BP was added to observe 
the specificity of antibody binding. The antibody binds to the C-terminal peptide 
(MSVSTDTSAEA) of CB1, located in the cytoplasm. Initial dilution value for our antibody and 
BP were determined previously (personal communication, Table 37). Our antibody was diluted 
200x (unless stated otherwise) in dilution buffer, while the BP was diluted 80x.  
Both monoclonal Santa Cruz antibodies were new on the market, and lacked reference experiments 
for ICC staining, therefore we diluted CB1 antibody 50x in dilution buffer, as recommended by 
the manufacturer (Table 37). Epitope sequence and location is unknown, as the manufacturer did 
not provide this information.  
In general, polyclonal CB1 antibody showed more promising results in CB1 detection, as 
monoclonal antibody failed to detect CB1 in all tested cell lines, apart from T-47D, even with as 
low a dilution as 50x (Figure 13, Figure 14, Table 59). 
4.4.1.1 MCF-7 cell line 
No visible CB1 staining was observed with both Abcam and Santa Cruz CB1 antibodies in 
hormone positive MCF-7 cell line (Figure13a, Figure 14a). 
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As MCF-7 is one of the experimentally most used breast cancer cell lines for ECS tests in breast 
cancer cells, we wanted to ensure negative receptor expression in our MCF-7 cells by testing 
whether lowering the Abcam antibody dilution from 200x to 100x would result in successful 
receptor detection. However, no CB1 staining was observed even after increasing the antibody 
concentration (200x to 100x dilution) (Figure 15).  
Our results have led us to conclude that both polyclonal and monoclonal CB1 antibodies are unable 
to detect CB1 in MCF-7 cell line, with dilution as low as 100x and 50x.  
There are no MCF-7 uniform CB1 expression values in the literature and databases. The available 
literature suggests that MCF-7 expresses CB1 receptors, whereas CCLE results differ (Table 49).  
Our WB results, however, showed positive MCF-7 expression (Figure 12) with both tested 
antibodies. Taken together, these results indicate that both antibodies are inappropriate for ICC 
detection.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
Figure 15. CB1 detection in MCF-7 cell line with increased antibody concentration (200x to 100x dilution). Even 
though some staining was observed after lowering the dilution from 200x to 100x (black arrows), it should be 
interpreted as unspecific, as the same staining was observed in the combination with the BP. Cell nuclei were 
counterstained using haematoxilyn (blue). Scale bar represents 50 µm.  
4.4.1.2 MDA-MB-231 cell line 
Interestingly, MDA-MB-231, a triple negative cell line showed positive low intensity Abcam CB1 
staining in the cytoplasm and nucleus in both tested duplicates (Figure 13b). Even though the BP 
was unable to fully obstruct antibody binding, in the combination, lower staining was observed 
(Figure 13b). Nuclear and cytoplasmic expression could be correlated with the C-terminal 
cytoplasmic epitope and internalized CB1 expression. However, additional result validation is 
needed for nuclear/cytoplasmic expression. 
An observation that emerged from the comparison of polyclonal and monoclonal antibody results 
is that monoclonal lacks cytoplasm/nuclear staining as no visible staining is observed in both tested 
duplicates (Figure 14b).  
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According to available published data, MDA-MB-231 uniformly expresses CB1 (Table 49).  
WB results show high intensity positive signal for Abcam and low intensity for Santa Cruz CB1 
detection (Figure 12).  
Therefore, the positive WB signal and no observed staining in both tested duplicates with dilution 
as low as 50x, has led us to conclude that Santa Cruz CB1 antibody is unfit for ICC detection.  
4.4.1.3 SK-BR-3 cell line 
HER2 positive SK-BR-3 cell line showed low intensity nuclear staining with polyclonal antibody. 
However, these results should be taken with caution as similar staining was observed with BP 
combination, which could indicate unspecific binding (Figure 14c). Therefore, additional result 
validation is needed for nuclear detection of CB1 in SK-BR-3 cell line. 
It was found that Santa Cruz CB1 antibody is unable to stain CB1 in both SK-BR-3 duplicates. 
These results did not match the low intensity nuclear staining with Abcam CB1 antibody (Figure 
15c). 
Based on available literature and CCLE data, SK-BR-3 lacks CB1 expression (Table 49).  
Although both antibodies were able to detect CB1 with the WB method (Figure 12), interestingly, 
high intensity CB1 WB signal was observed with the Santa Cruz antibody, which points to the 
probability that monoclonal Santa Cruz antibodies are unfit for ICC CB1 detection.  
4.4.1.4 MDA-MB-361 cell line 
No visible staining was observed in both tested duplicates of hormone positive MDA-MB-361 cell 
line with both tested antibodies (Figure 13d, Figure 14d).  
As far as we know, MDA-MB-361 lacks receptor expression in available literature data  
(Table 49), whereas, in the CCLE database, it is reported to achieve the highest levels of mRNA 
expression. 
WB results showed that both polyclonal and monoclonal antibodies were able to detect CB1, but 
with low intensities (Figure 12). This could be interpreted that both antibodies were unfit for ICC 
CB1 detection, or that MDA-MB-361 has low levels of receptor expression, which could not be 
detected with ICC staining. Further mRNA expression tests will clarify divergence between 
methods.  
4.4.1.5. T-47D cell line 
Uniform positive CB1 staining with both tested antibodies was observed solely in hormone 
positive T-47D cell line. 
High intensity membrane staining could be easily observed with polyclonal antibody; however, 
background staining should not be disregarded (Figure 13e). Addition of BP allowed us to 
distinguish between the specificity of antigen recognition.  
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Positive monoclonal CB1 staining was observed solely in T-47D cell line. In both duplicates, low 
intensity membrane staining was observed, which correlates with positive Abcam CB1 results 
(Figure 14e). 
Even though our ICC staining results differ from available mRNA expression values, they are 
consistent with literature data (Table 49) and the previously confirmed high intensity WB signals 
(Figure 12).  
Equally to obtained WB signal intensities, ICC Abcam shows high intensity, while Santa Cruz 
shows moderate intensity staining. 
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Figure 13. Immunocytochemical staining of CB1 receptor in selected breast cancer cell lines using polyclonal 
Abcam Anti-Cannabinoid Receptor I antibody and BP. Cell nuclei were counterstained using haematoxilyn (blue). 
Scale bar represents 50 µm. CB1 dilution 200x, Blocking peptide (BP) dilution 80x 
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Figure 14. Immunocytochemical staining of CB1 receptor in selected breast cancer cell lines using monoclonal 
Santa Cruz CB1 antibody. Cell nuclei were counterstained using haematoxilyn (blue). Scale bar represents 50 µm. 
CB1 dilution 50x. 
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4.4.2 CB2 immunolabeling  
Apart from the different antibody dilution, the same protocol was used in CB2 detection with 
Abcam polyclonal CB2 antibody. Our antibodies were diluted 500x, while the BP was diluted 50x, 
unless stated otherwise. As for CB1 antibody, dilution values for both antibody and BP were 
established previously (personal communication Table 37). The manufacturer did not provide 
information on the antibody binding epitope and localization.  
The same protocol was followed for Santa Cruz monoclonal CB2 antibody staining as for CB1. 
The antibody was diluted 50x in dilution buffer, as recommended by the manufacturer (Table 37). 
Epitope sequence and location is unknown, as the manufacturer did not provide this information.  
In general, reverse results were obtained for CB2 staining in comparison to CB1. Apart from  
T-47D, polyclonal antibody was unable to detect CB2 in selected cell lines, while high intensity 
monoclonal CB2 staining was observed across all tested cell lines. This positive CB2 staining 
should be treated with caution, as the high intensity staining could be hard to validate, and could 
be due to unspecific antibody binding (Figure 16, Figure 17, Table 53). 
4.4.2.1 MCF-7 cell line 
We were surprised to find that CB2 Abcam antibody was unable to detect CB2. Even after 
lowering the dilution from 500x to 200x (Results not shown), no staining is observed (Figure 16a). 
On the other hand, we achieved positive membrane CB2 staining using monoclonal antibody, 
which differs from polyclonal CB2 antibody staining (Figure 17a).  
Unlike for CB1, database values showed low expression of CB2 mRNA, which corresponds to 
literature data (Table 49). 
Both antibodies were able to detect CB2 using WB (Figure 12). 
Due to the inability to detect CB2, even at high antibody concentration (200x), while being able 
to detect specific CB2 signal using the WB method, we can conclude that Abcam Anti-CB2 
antibody is inappropriate for ICC CB2 detection.  
Despite the fact that positive Santa Cruz CB2 WB signal provided additional validation of ICC 
results, the Santa Cruz CB2 staining results should be regarded as false positive, until validated 
otherwise.  
4.4.2.2 MDA-MB-231 cell line 
Low intensity cytoplasmic staining was observed in both duplicates using polyclonal CB2 
antibody (Figure 16b). Regrettably, no visible staining difference was observed in BP addition, 
which hinders result validation.  
Monoclonal CB2 achieved over-staining, with evident unspecific background staining (Figure 
17b). Possible CB2 cytoplasm staining, which would correlate with Abcam results is hard to 
unfold, due to high amount of unspecific signals (Figure 18).  
Positive expression data is in line with CCLE and literature for CB2 expression (Table 49).  
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WB results showed positive specific detection of CB2 with both tested antibodies (Figure 12), 
which helped in validating cytoplasmic staining and the antibody general ability to detect CB2 
with the ICC method. Further work on optimizing Santa Cruz CB2 dilution could help in validating 
antibody specificity.  
 
Figure 18. Monoclonal Santa Cruz CB2 antibody shows unspecific staining in MDA-MB-361 cell line. Cell 
nuclei were counterstained using haematoxilyn (blue). Scale bar represents 50 µm. CB2 dilution 50x. 
4.4.2.3 SK-BR-3 cell line 
No visible staining is observed in both duplicates using polyclonal CB2 antibody, with defined 
dilution value (Figure 16c). As SK-BR-3 is known to express CB2 to achieve possible detection, 
we tried lowering the dilution from 500x to 200x, which proved unsuccessful (Results not shown).  
Low CB2 antibody dilution with monoclonal antibody, showed similar unspecific staining, seen 
in other tested cell lines (Figure 17c). As SK-BR-3 is known to express CB2, we tried to increase 
the dilution from 50x to 200x, to determine whether it would help in result validation (Figure 19). 
Unfortunately, the dilution change lowered the background staining, but showed no CB2 relevant 
staining in SK-BR-3 cell line.  
However, available CCLE and literature data showed positive CB2 expression, which differed 
from our staining results (Table 49). 
Given that both antibodies were able to detect WB CB2 signals with satisfactory intensities  
(Figure 12), but failed to achieve the same results with various tested concentrations, we can 
conclude that both antibodies are unfitting for CB2 detection in SK-BR-3 cell line.  
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Figure 19. Increasing the dilution of monoclonal Santa Cruz CB2 antibody shows negative staining in SK-BR-
3 cell line. Cell nuclei were counterstained using haematoxilyn (blue). Scale bar represents 50 µm. CB2 dilution was 
increased from 50x (left) to 200x (right).  
4.4.2.4 MDA-MB-361 cell line 
No ICC staining was observed in both duplicates with using Abcam CB2 antibody (Figure 16d). 
Low intensity staining, in comparison to other tested cell lines, was observed in both Santa Cruz 
CB2 duplicates, but should be taken with caution until additional validation (Figure 17d). 
Interestingly, MDA-MB-361 showed positive CB2 mRNA expression, however, there is no 
available literature data on expression (Table 49). 
Due to positive WB detection with both antibodies (Figure 12), we can conclude that Abcam CB2 
antibody is unfit for ICC CB2 detection, while additional validation for Santa Cruz antibody is 
needed.   
4.4.2.5 T-47D cell line  
Equivalently to CB1 staining results, T-47D cell line showed the most promising results for CB2 
ICC staining for both antibodies.  
The obtained polyclonal CB2 results showed low intensity membrane staining, with additional 
unspecific background staining (Figure 16e). Addition of the BP lowered background staining 
(Figure 16e). Lowering the dilution from 500x to 200x showed higher intensity staining (results 
not shown).  
At a low 50x dilution monoclonal CB2 staining showed high intensity membrane staining, with 
low unspecific background binding (Figure 17e). As positive CB2 Abcam staining results were 
obtained with the cell line known from literature data to express CB2, we increased the dilution 
from 50x to 200x in hopes of validating our antibody binding. Increasing the dilution removed 
background staining, while withholding membrane staining in lower intensity (Figure 20). Even 
though the unspecific binding of the CB2 antigen hinders results validation across tested cell lines, 
CB2 in T-47D should be regarded positive until proven otherwise.  
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As anticipated, positive staining results correlated with database and literature data (Table 49), but, 
interestingly, differed from our WB results (Figure 12), as our Abcam antibody was unable to 
detect CB2 with the WB method. Given the unexpected results, it is important to determine the 
nature of the WB results, as the loss of CB2 expression in our cell line would mean unspecific ICC 
staining. 
Santa Cruz CB2 staining results correlate with obtained WB signals.   
 
Figure 20. Dilution of monoclonal Santa Cruz CB2 antibody effects staining in T-47D cell line. Cell nuclei were 
counterstained using haematoxilyn (blue). Scale bar represents 50 µm. CB2 dilution was modified from 50x (left) to 
200x (right). 
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Figure 16. Immunocytochemical staining of CB2 in selected breast cancer cell lines using polyclonal Abcam 
Anti-Cannabinoid Receptor II antibody and BP. Cell nuclei were counterstained using haematoxilyn (blue). Scale 
bar represents 50 µm. CB2 dilution 500x, Blocking peptide (BP) dilution 50x. 
Fran Krstanović. Določitev kanabidoidnih receptorjev v celičnih linijah raka dojke. Magistrska naloga. Univ. 
v Ljubljani, FKKT, 2019.  
 
59 
 
 
Figure 17. Immunocytochemical staining of CB2 receptor in selected breast cancer cell lines using monoclonal 
Santa Cruz CB2 antibody. Cell nuclei were counterstained using haematoxilyn (blue). Scale bar represents 50 µm. 
CB2 dilution 50x. 
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4.4.3 Comparison of ICC analysis with both sets of CBs antibodies 
As ICC results deviate between tested antibodies and cell lines, for easier interpretation, the results 
are summarized in Table 53. 
Table 53. Summary of Cannabinoid receptor expression in tested breast cancer cells using ICC method.  
Cell line 
Cannabinoid receptors 
CB1 Abcam CB1 Santa Cruz CB2 Abcam CB2 Santa Cruz 
MCF-7 - - - 
+? 
L: M? 
MDA-MB-231 
+ 
L: N,C 
- 
+ 
L: C 
+++? 
L:? 
SK-BR-3 
+? 
L: N? 
- - - 
MDA-MB-361 - - - 
+? 
L: M? 
T-47D 
+++ 
L: M 
+ 
L: M  
+ 
L: M 
+++ 
L: M 
 
Legend:  
Expression intensity: High expression (+++), moderate expression (++), Low expression (+), no expression (-).  
Localization (L): Nuclear (N), cytoplasmic (C), membrane (M). Further validation needed (?). 
4.5 Effect of CBD on breast cancer cells viability 
Cell viability assay was performed by MTT as described in Methods to determine response of 
different subtypes of breast cancer to cannabidiol (CBD) alone and in combination with standard 
therapeutics. We selected 3 breast cancer cell lines with different receptor status: T-74D 
(ER+/PR+/HER2-), SK-BR-3 (ER-/PR-/HER2+) and triple-negative MDA-MB-231 cell lines.  
Each cell line was treated with CBD or the therapeutic alone (Table 41), and in combination 
treatment. Half maximal inhibitory concentration (IC50) was generated from the dose response 
curves by GraphPad Prism program for CBD treatment in each cell line. Although CBD has been 
tested in combination with first-line therapies for various cancers, to our knowledge, we are the 
first to test and report CBD in combination with selected compounds (TAM, HER, CIS) on the 
selected (T-47D, SK-BR-3, MDA-MB-231) breast cancer cell lines [30,46].   
4.5.1 Treatment response data of selected breast cancer cell lines from literature  
Reference values for treatment and response of selected cell lines with cannabinoids were obtained 
from relevant studies, as cited in the Reference section and summarized in Table 54. 
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Table 34. Overview of cell viability assays using cannabinoids on selected breast cancer cell lines.  
Cell line Treatment Response Method Reference 
T-47D 
Natural CBD IC50=5 µM 
24h treatment 
MTT  
[48] 
Pure THC IC50=2.8 µM 24-48h treatment 
Crystal violet  
[49] 
CDP IC50=2.2 µM 
Pure THC IC50=6.7 µM 
72h treatment 
MTT 
[50] 
SK-BR-3 
Natural CBD 
~60 % inhibition at 
8 µM 
24h treatment 
MTS 
[51] 
Pure THC IC50=4.5 µM 
72h treatment 
MTT 
[50] 
MDA-MB-231 
Natural CBD IC50=5 µM 
24h treatment 
MTT  
[48] 
CBD 
70 % inhibition at ~ 
4 µM 
24h treatment 
MTT 
[52] 
Natural CBD IC50=7.5-8 µM 
24h treatment 
MTS 
[53] 
Natural CBD IC50=25 µM 
12h treatment 
MTS 
[54] 
Natural CBD IC50=10.6 µM 
Daily treatment (4d) 
Crystal violet 
[55] 
CBD IC50=1.3 µM 
Daily treatment (3d) 
MTT 
[56] 
Pure THC IC50=2.8 µM 24-48h treatment 
Crystal violet  
[49] 
CDP IC50=2.1 µM 
Pure THC IC50=5 µM 
72h treatment 
MTT 
[50] 
 
4.5.2 Effects of CBD on T-47D cell line viability  
Hormone positive T-47D cell line showed the most promising treatment response in  
concentration-dependent loss of cell viability with CBD treatment (Figure 21a). Steadily 
increasing CBD concentrations generated a slope response curve in cell viability. The measured 
IC50 value for CBD treatment in T-47D cells was 24.3 µM (Figure 21b). We have obtained 
statistically significant results suggesting a possible synergistic effect of therapeutic combination 
with tamoxifen (TAM) (Figure 21a).  
To our knowledge, the only known similar research was reported by Sultan et al., [48] measuring 
CBD treatment IC50 value at 5 µM. Literature data shows a non-uniform treatment response in  
T-47D cell line with pure THC (IC50=2.8 µM [49], IC50=6.7 µM [50]) or with cannabis drug 
preparation (CDP,  botanical preparation composed of over 30 compounds) with IC50=2.2 µM 
[49]. We are of the opinion that the CBD effects on tumor cell viability is a promising adjuvant 
treatment option, as CBD lacks psychoactive traits in contrast to pure THC or CDP. 
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Viability assay measured inhibitory activity on cell viability of TAM with IC80 value at 2.5 µM 
(Figure 21a), which was used in combination treatment with a range of CBD concentrations. 
Interestingly, only the lowest and highest CBD concentrations (1 µM, 20 µM, 30 µM) showed a 
possible synergistic effect in combination with TAM, achieving statistically significant values with 
30 µM CBD in combination with 2.5 µM TAM. 
In comparison, combination treatment of pure THC-TAM and CDP-TAM (2.5 µM) achieved an 
even higher synergistic effect, compared to TAM (5 µM), as shown by Blasco-Benito et al [49]. 
 
Figure 21. Cell viability and CBD half maximal inhibitory concentration (IC50, µM) on T-47D  
(ER+/PR-/HER2-). a) Cell viability on BC cells was determined by metabolic activity scores (MTT assay) after a 48 
h exposure to CBD alone or in combination with tamoxifen (TAM). Results are expressed as percent of treated versus 
control non-treated cells, non-treated set as 100 %. Each value represents the mean ± SD (n = 3 independent 
experiments, each in triplicate). *P < 0.05, **P < 0.01, ***P < 0.001 versus the control group (t-test). Statistical 
analysis was performed using one-way ANOVA with GraphPad Prism 6 software. (San Diego, CA). b) Data are 
expressed as IC50 of CBD values generated from the dose response curves by GraphPad Prism (n= at least 3 
experiments).  
4.5.3 Effects of CBD on SK-BR-3 cell line viability  
CBD treatment of HER2 positive, hormone negative SK-BR-3 cell line did not show a  
dose-dependent response to CBD treatment (Figure 22a), as did T-47D cell line (Figure 21a). 
Threshold dependent treatment response with CBD alone, and possible synergistic effect with 
HER were observed. Our cells showed more resistance to CBD treatment than available reference 
data, as we measured IC50 value at 23.7 µM in comparison to a 60 % inhibition at approximately 
8 µM CBD obtained by Mckallip et al [51]. Caffarel et al., measured IC50 value for pure THC 
treatment at 4.5 µM [50].  
We found also high cell resistance to HER treatment, as concentrations as high as HER 50 µg/ml 
did not trigger a decrease in viability (Figure 22a), and with concentration of about 100 µg/ml were 
measured as IC80 value. Similarly, Vanderhoeven, et al., [57] reported that a high dosage of HER 
is needed to trigger a viability response in SK-BR-3 cell line, with effect on reducing viability 
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observed only above 100 µM. High HER concentrations are considered undesirable, as they could 
limit possible clinical applications of cell treatment.  
High concentrations of 50 µM and 100 µM HER were tested in combination treatment. Possible 
synergistic effect was observed solely in combination with high concentrations  
(HER 50/100 µg/ml + CBD 20 µM) of both substances; however, statistically significant values 
were not confirmed.  
 
Figure 22. Cell viability and half CBD maximal inhibitory concentration (IC50, µM) on SK-BR-3 (ER-/PR-
/HER2+). a) Cell viability on BC cells was determined by metabolic activity scores (MTT assay) after a 48 h exposure 
to CBD alone or in combination with Herceptin (HER). Results are expressed as percent of treated versus control non-
treated cells, non-treated cells set as 100 %. Each value represents the mean ± SD (n = 3 independent experiments, 
each in triplicate). ***P < 0.001 versus the control group (t-test). Statistical analysis was performed using one-way 
ANOVA with GraphPad Prism 6 software. (San Diego, CA). b) Data are expressed as IC50 of values generated from 
the dose response curves by GraphPad Prism (n=at least 3 experiments). 
4.5.4 Effects of CBD on MDA-MB-231 cell line viability 
Similar to SK-BR-3, triple negative MDA-MB-231 cell line showed threshold response to CBD 
treatment (Figure 23a). Here, 72-h treatment was used as 48-h treatment showed no consistent 
results. No significant response was observed in cell viability until the 30 µM threshold was 
reached, with 40 and 50 µM concentrations almost completely abolishing cell viability. We 
measured our IC50 values at 39.5 µM (Figure 23b), which is inconsistent with literature values. 
However, the literature data differ  considerably as (Table 54), Murase et al., [52] achieved 70 % 
inhibition around 4 µM, Sultan et al., [48] measured IC50 at 2.2 µM, Shrivastava et al., [53] around 
7.5-8 µM, while Takeda et al., [54] were unable to achieve IC50 values with concentrations as high 
as 25 µM. Ligresti et al., [55] measured IC50 at 10.6, although using a method of daily CBD 
treatment, and measuring viability with trypan blue. McAllister et al., [56] also used the daily 
treatment method, and measured IC50 with the MTT test at 1.3 µM for CBD.  
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To compare with pure THC and CDP treatment in MDA-MB-231 cell line, Blasco-Benito et al., 
[49] measured IC50 values at 2.8 µM and 2.1 µM, while Caffarel, et al., [50] achieved 50 % 
inhibition at 5 µM for pure THC treatment.  
Preliminary tests measured cisplatin (CIS); IC80 value at 2.5 µM (Figure 23a), which was later 
used in combination treatment.  
Possible threshold synergetic response was observed in combination treatment. However, no 
drastic change in cell viability was observed with the addition of 2.5 µM CIS, until the threshold 
of 30 µM CBD was surpassed. We found that the combination of 30 µM CBD and 2.5 µM CIS 
showed statistically significant values for impairing cell viability.  
Combination treatment of MDA-MB-231 with pure THC or CDP and cisplatin used by Blasco-
Benito et al., [49], did not show uniform results. Pure THC at a low concentration was unable to 
show antiproliferative effect, while the combination of CDP and THC was able to lower cell 
viability [49]. Interestingly, although Blasco-Benito et al., [49] achieved 60 % inhibition with 100 
µM CIS, our preliminary results showed total inhibition for the same concentration.   
 
Figure 23. Cell viability and CBD half maximal inhibitory concentration (IC50, µM) on MDA-MB-231 (ER-
/PR-/HER2-). a) Cell viability on BC cells was determined by metabolic activity scores (MTT assay) after a 78-h, 
exposure to CBD alone or in combination with cisplatin (CIS). Results are expressed as percent of treated versus 
control non-treated cells, non-treated cells set as 100 %. Each value represents the mean ± SD (n = 3 independent 
experiments, each in triplicate). ***P < 0.001 versus the control group (t-test). Statistical analysis was performed 
using one-way ANOVA with GraphPad Prism 6 software. (San Diego, CA). b) Data are expressed as IC50 of values 
generated from the dose response curves by GraphPad Prism (n= at least 3 experiments). 
4.5.5 Comparison of cell viability among tested cell lines 
CBD treatment alone affected all three tested cell lines at half maximal inhibitory concentration 
range of 20-40 µM, with MDA-MB-231 showing the highest resistance (IC50=39.5 µM) in 
comparison to T-47D (IC50=24.3 µM) and SK-BR-3 (IC50=23.7 µM). In general, CBD 
concentrations above 30 µM significantly decreased cell viability in all tested cell lines. Response 
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to CBD treatment differed between these cell lines, as T-47D showed a concentration-dependent 
decrease in cell viability, while threshold-like response was observed in MDA-MB-231 and  
SK-BR-3 cell line.  
We measured IC80 values for both Tamoxifen (TAM) in T-47D cells and cisplatin (CIS) in  
MDA-MB-231 cells at concentrations as low as 2.5 µM, while a concentration range as high as 
50-100 µg/ml was needed to trigger the same decrease in cell viability in SK-BR-3 Heceptin (HER) 
treatment. 
To sum up, the results indicate synergistic effects of combination treatment with the relevant 
therapeutics in all three tested cell lines at CBD concentrations 20 µM or higher. Interestingly, 
however, in T-47D cell line there are three possible synergistic effects with 2.5 µM TAM, first at 
lower concentration (1 µM CBD), second and third at higher concentration (20 µM and 30 µM) 
(statistically significant) CBD. Statistically significant synergistic results were also demonstrated 
for MDA-MB-231 (30 µM CBD + 2.5 µM CIS) combinational treatment. In SK-BR-3 cell line 
combinational treatment, no statistically significant results were obtained, although possible 
synergistic effect was observed in combination with high concentrations of HER (50/100 µg/ml) 
and CBD (20 µM). 
4.6 General discussion  
Apart from surgery, phenotype-specific system therapy is used to prolong survival and prevent 
cancer recurrence. Recent investigations revealed that the endocannabinoid system (ECS) is 
involved in many diseases, including cancer. The endocannabinoid receptors are proteins similar 
to G-proteins found in the central nervous system (Type 1 receptor, CB1) and in the immune 
system (Type 2 receptor, CB2). Phtyocannabinoids, such as tetrahydrocannabinol (THC) also bind 
to CB1, whereas cannabidiol (CBD) binds preferentially, but weakly to CB2 and triggers a plethora 
of biological effects. Presumably, the subsequent intracellular signaling results in cellular 
responses, some having potential therapeutic effects.  
We used  two sets of antibodies for immunocytochemistry (ICC) and Western Blot analysis, 
polyclonal by Abcam (Cambridge, UK), and monoclonal by Santa Cruz (Santa Cruz, USA). 
The presence of CB receptors and their protein levels were assayed by Western blot of cell extracts. 
Western blots were normalized and quantified against the housekeeping protein GAPDH. 
Both polyclonal and monoclonal CB1 antibodies detected the same load of cell protein with 
different intensities in selected breast cancer cell lines. The polyclonal antibody was able to detect 
CB1 solely in a dimer form, with observed signals at 111-113 kDa, which corresponds to the 
double molecular weight of CB1, while monoclonal antibody detected CB1 solely as monomers, 
with signals that correspond to a molecular weight of 51-53 kDa.  
Both Abcam and Santa Cruz antibodies detected CB2 at the predicted band size; 36-42 kDa for 
polyclonal and 63-68 kDa for monoclonal. Similar to CB1 detection, signal intensity varied among 
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the tested cell lines. The discrepancy between detected molecular weights can be correlated with 
antibody clonality. 
We have confirmed the presence of CB1 and CB2 in breast cancer cell lines, present on the cell 
membrane and in the cytoplasm.   
However, ICC results using various monoclonal and polyclonal antibodies from the two providers 
did not show identical immunolabeling of either CB1 or CB2 antigens, even in the same cancer 
cell line.  
Polyclonal (Abcam) antibodies labeling also differed among breast carcinoma cell lines: CB1 
antibody labelled shows positive, although with low intensity of staining, whereas CB2 antibody 
was generally of poor reactivity against the CB2 antigen. Synthetic blocking peptide (BP) was 
added in combination with the respective antibody, as additional validation of labelling specificity. 
Monoclonal (Santa Cruz) antibodies showed much lower staining to non-staining of CB1 in all 
tested cell lines, even those with high antibody concentrations. However, strong, although non-
specific background staining was observed with CB2 antibodies, hindering their validation.  
Specifically, T-47D, a hormone-positive cell line labeled positive for CB1 and CB2; mostly 
membrane staining with both tested sets of antibodies was observed, which is in agreement with 
literature data.  
MDA-MB-231 cell lines showed positive, but low intensity nuclear and cytoplasmic staining for 
both CB receptors using a polyclonal antibody was detected.  
SK-BR-3 cell line showed positive, but low intensity nuclear staining using Abcam CB1 antibody.  
Generally, in our study, no significant staining was observed in both MCF-7 and MDA-MB-361 
cell lines using both sets of CBs antibodies.  
It can be concluded that polyclonal (Abcam) antibodies show, in general, a more intense 
immunolabeling in particular to CB1, and enable subcellular localization, whereas monoclonal 
(Santa Cruz) are unable to detect CB1 antigen. However, a reverse trend is observed in CB2 
detection. Monoclonal antibody stained the target with high intensity, while polyclonal antibody 
detected low to antigen.  
Interestingly, in WB Abcam CB2 antibody was able to detect positive CB2 signals in all selected 
cell lines, except in T-47D, while in ICC positive staining was observed. Positive Abcam CB2 ICC 
staining was also observed in MDA-MB-231 cell line. High intensity WB signals were observed 
across all tested cell lines with Santa Cruz antibody, which correlates with high-intensity ICC 
staining. 
Abcam CB1 failed to stain MCF-7, SK-BR-3 and MDA-MB-361 with ICC method. A similar 
pattern was observed with Santa Cruz antibody, as apart from T-47D, no ICC staining was 
observed, while positive WB signals were obtained for all tested cell lines. 
These results indicate that ICC and WB mainly differ from one another in all cell lines. 
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We have shown that using the non-psychoactive CBD alone lowers the cell viability either in a 
concentration-dependent manner (T-47D) or in a threshold response manner (MDA-MB-231,  
SK-BR-3).  
Cell viability tests indicate that CBD could have a future in breast cancer treatment. It has been 
reported that CBD in combination with regular therapy could minimize the potential side effects 
[27,28],[30], while also tackling the problem of growing cancer resistance to standard therapy  
[1-3]. Tamoxifen was tested as standard therapy for hormone-positive T-47D cells, Herceptin for 
HER2+ SK-BR-3 cells and cisplatin for triple-negative MDA-MB-231 cells. 
In general the selected breast cancer cell lines showed a slightly higher resilience to cannabinoid 
treatment, when compared to published data (Table 54), with higher IC50 values, although within 
the µM concentration range. In general, CBD concentrations above 30 µM decreased cell viability 
drastically in all tested cell lines. Differences among experiments are due to various factors, such 
as cell passages and media variations, and most importantly, the origin (natural or synthetic), and 
the purity of CBD products.   
An important observation is that hormone-positive T-47D showed the most promising results 
among tested cell lines. Concentration-dependent decrease in cell viability was observed with 
CBD, as well as a possible synergistic effect with tamoxifen combination therapy.  
Even though both HER2-positive SK-BR-3 and triple-negative MDA-MB-231 cells, showed 
higher resilience to CBD treatment reported than in the literature, a threshold decrease in viability 
with CBD treatment was observed.  
Combination therapy with Herceptin and CBD shows possible synergistic effects at selected 
concentrations in HER2-positive SK-BR-3. A similar pattern was observed with combination 
therapy in triple-negative MDA-MB-231 cells. CBD and cisplatin treatment showed possible 
synergistic effects at selected concentrations.  
We are of the opinion that the potential usage of CBD in triple negative breast cancer could be a 
breakthrough as this type of cancer is fairly resistant to therapy, while we are also lacking new 
potential therapeutic targets. 
We propose that future research should focus on breast cancer mouse models, while also analyzing 
changes in metabolic pathways following CBD treatment. This step would be crucial, as it would 
give us an insight into the CBD mode of action, and the potential of exploiting it. Additional tests 
are needed to confirm the possible synergy between CBD and respective therapeutic options. It 
would also be important to test long-term CBD treatment, to determine the potential of breast 
cancer cell to develop resistance to CBD treatment.   
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5 CONCLUSION  
5.1 Selected breast cancer cell lines express various levels of CB receptor  
protein 
Using two sets of antibodies with different clonality: polyclonal (Abcam) and monoclonal (Santa 
Cruz), we have shown that the selected breast cancer cell lines express CB1 and CB2 protein.  
Polyclonal CB1 antibody detected the protein only in a dimer form, with observed bands at  
111-113 kDa, which corresponds to the double molecular weight reported for CB1. Monoclonal 
antibody detected CB1 with high specificity, but in the monomeric form, with the band that 
corresponds to a molecular weight of 51-53 kDa.  
Both polyclonal and monoclonal antibodies are able to detect CB2 at their predicted band size;  
36-42 kDa for polyclonal, and with high intensity at 63-68 kDa for monoclonal antibodies.  
Our work has led us to conclude that the discrepancy between detected molecular weight and signal 
intensity can be correlated with antibody clonality.  
Signal intensity varies among tested cell lines due to different levels of the receptors that they 
express. The results of polyclonal versus monoclonal antibodies differ among the selected breast 
carcinoma cells. They are presented below in a descending order from higher to lower expression, 
with a quantitative comparison of polyclonal with monoclonal antibodies: 
 The relative CB1 receptors levels detected with polyclonal antibodies, were the highest in 
T-47D cells, followed by MDA-MB-231>MCF-7>SK-BR-3>MCF-10A>MDA-MB-361 cell 
lines. However, with monoclonal antibodies the highest CB1 levels were found in SK-BR3T cells, 
followed by T-47D> MCF-7>MDA-MB-231> MCF-10A>MDA-MB-361 cell lines. 
 The relative levels of CB2 were found highest with polyclonal antibodies in MCF-10A 
cells, followed by MDA-MB-231>MDA-MB-361>MCF-7>SK-BR-3>T-47D cell line, whereas 
with monoclonal antibodies the relative amounts were highest in T-47D>MCF-10A> 
MDA-MB-231>MCF-7>SK-BR-3> MDA-MB-361. 
The observed results can be ascribed to both (1) different affinities and (2) the degree of 
dimerization in different cells lines. 
Comparisons between immunocytochemical and Western blot analyses  
A direct comparison of the two methods of CB receptor protein detection cannot be made due to 
(1) different morphologies of the selected breast cancer cells, (2) the intrinsic differences of the 
antibodies to bind native versus denatured proteins, and (3) the abovementioned differences in the 
dimerization of the CB1 and CB2 in various cell lines, which are detected with various affinities 
by different types of antibodies.  
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5.2 Cannabidiol (CBD) decreases the viability of breast cancer cells alone, and 
in combination with standard breast carcinoma cell subtype-specific therapy  
We have shown that using CBD alone lowered cell viability in either a  
concentration-dependent manner (T-47D) or in a threshold response manner (MDA-MB-231, SK-
BR-3).  
We have measured IC50 values for the selected cell lines in the concentration range of 20-40 µM. 
MDA-MB-231 shows the highest resistance (IC50=39.5 µM) in comparison to T-47D  
(IC50=24.3 µM) and SK-BR-3 (IC50=23.7 µM).  
Furthermore, it was found that specific concentrations of CBD in combination therapy with 
standard phenotype-specific therapeutics decreased cell viability, which confirms the following 
hypotheses.  
Our data indicate that T-47D cell line shows possible synergistic effects in combination with two 
concentrations with  2.5 µM tamoxifen (TAM), first at lower concentrations, 1 µM CBD, and 
second at higher concentrations above 20 µM CBD.  
Statistically significant synergistic results were obtained for MDA-MB-231 cell line at 30 µM 
CBD + 2.5 µM Cisplatin (CIS) combination treatment.  
However, for SK-BR-3 cell line treatment, a possible synergistic effect was observed only in 
combination with high concentrations of HER, above 50 (also 100) µg/ml and 20 µM CBD.  
 
To conclude, we were able to successfully confirm both hypotheses that were set at the beginning 
of the experimental research. The results represented in the thesis will be a great cornerstone in 
the further unveiling and possible exploitation of the ECS as a therapeutic target in breast cancer 
therapy.      
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Background 
Approximately 70-80 % of all known breast cancers are estrogen receptor alpha (ERα) positive (1). Common 
endocrine therapy includes selective estrogen receptor modulator (SERM) tamoxifen, which binds to ERα and inhibits 
estrogen dependent signaling. Cannabinoids have recently been demonstrated to induce anti-tumor responses in certain 
cancer types, including breast carcinoma. Cannabinoid receptors (CBRs) are G-protein coupled receptors found in the 
central nervous system (CB1) and in the periphery (CB2). Cannabinoids can also activate other receptors, like GPR55. 
Recent studies have shown that tamoxifen acts as inverse agonist on CBRs (2) and may interfere with potential 
application of cannabinoids in breast cancer treatment. 
  
Objectives 
The aim of the study is to evaluate the expression of CB1, CB2 and GPR55 receptors in selected breast cancer cell 
lines of different subtypes and with different hormone status (ER+/PR+/HER2-, ER-/PR-/HER2+ and triple-negative).  
 
Methods 
The expression levels of CBRs in breast cancer cell lines were analyzed using immunocytochemistry, comparing two 
different primary antibodies (Abcam, Santa Cruz Biotechnology). Optimal concentration range and specificity of 
selected antibodies against CBRs was determined by Dot blot and Western blot, respectively. 
 
Results 
We tested one of the most used polyclonal antibodies against CBRs (Abcam), and were among the first to test the new 
monoclonal antibodies (Santa Cruz Biotechnology). Cell lines T-47D and MDA-MB-231 are positive for CB1 and 
CB2, while SK-BR-3 is positive for CB1. CBRs expression results differ among the cell lines. Only T-47D is positive 
for GPR55. 
 
Conclusion 
Hormone positive T-47D, triple-negative MDA-MB-231 and HER2 positive SK-BR-3 express one or more CBRs and 
are thus susceptible to manipulation of the endocannabinoid system. 
 
References  
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Cannabidiol increases potency of tamoxifen in inhibiting breast cancer cell viability  
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Background 
Breast cancer (BC) is a very heterogeneous disease. Currently, decision-making regarding treatment of individual 
patients is based on several factors, most important of them are expression of estrogen receptors (ER), progesterone 
receptors and receptor for epidermal growth factor 2  (HER2).  Common endocrine therapies include selective estrogen 
receptor modulator tamoxifen (TAM), aromatase inhibitors (AIs) and selective estrogen receptor degrader fulvestrant. 
Inhibitors of cyclin dependent kinases 4/6 (iCDK 4/6) in combination with AIs or fulvestrant, are recently being used 
in treatment of metastatic BC. Trastuzumab, an anti-HER2 monoclonal antibody, is a cornerstone treatment in HER2 
positive disease. Next to other chemotherapeutic drugs, cisplatin is commonly used in triple-negative BC. 
Cannabinoids, a therapeutic option in the palliative treatment of cancer patients, have recently been demonstrated to 
induce anti-tumor response in certain cancer types, including BC. Reportedly, cannabinoids have been shown to exert 
antiproliferative and antimetastatic activities against BC cells. The effects of cannabinoids on signaling pathways in 
cancer cells are conferred via G-protein coupled cannabinoid receptors (CBRs) type 1 (CB1) and type 2 (CB2), other 
receptors (e.g. GPR55, TRPV2) or in a receptor-independent way. Cannabidiol (CBD) is a ligand of CB1 and CB2 
receptors and is not psychoactive. Recent studies have shown that TAM acts as inverse agonist on CBRs but the 
significance of this interaction is unknown.  
 
Objectives 
The aim of the study was to evaluate the effect of CBD on cell viability of selected BC cell lines of different subtypes 
(ER+, HER2+, triple-negative) alone and in combination with different BC therapies (TAM, fulvestrant, fulvestrant 
+ iCDK 4/6, trastuzumab and cisplatin). 
 
Methods 
The expression of CBRs in BC cell lines (MCF7, MDA-MB-231, MDA-MB-361, T-47D, SK-BR-3) was confirmed 
using western blot (WB). We used polyclonal antibodies against CB1 and CB2 receptors (ab23703 and ab45942, 
Abcam), and were among the first to test the monoclonal antibodies (sc-518035 and sc-293188, Santa Cruz 
Biotechnology) that exhibit lower levels of the requested specificity. All tested cell lines (T-47D, MDA-MB-231, SK-
BR-3) were exposed to different concentrations of CBD. In addition, T47D cell line (ER+) was exposed to 
combination of CBD and endocrine therapy (TAM, fulvestrant), as well as combination of fulvestrant and palbociclib. 
Triple-negative MB-231 cell line was exposed to combination of CBD and cisplatin and SK-BR-3 cell line (HER2+) 
to CBD and trastuzumab.  
 
Results and Conclusions 
CB1 and CB2 receptors are expressed in all tested BC cell lines. CBD decreased cell viability of all tested cell lines, 
however in MB-MDA-231 and SK-BR-3 cell lines only in above 25 µM concentrations. We are first to demonstrate 
that CBD increases the potency of TAM in inhibiting T-47D cell line viability. So far we could not confirm similar 
effect of CBD in combination with cisplatin, trastuzumab, fulvestrant alone or the combination of fulvestrant and 
iCDK 4/6.  
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